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INTRODUCTION 
The Siddha Medicine  is one of the ancient medical system known to 
mankind.  
"Siddha medicine" means medicine that is perfect. It is claimed to revitalize 
and rejuvenate dysfunctional organs that cause the disease and to maintain the ratio 
of vatham, pittam and kapham. 
SIDDHA  is a unique system of medicine providing better cure for all 
chronic ailments like carcinoma, Syphilis, respiratory diseases, infectious diseases, 
diabetes, dermatological cases, autoimmune disorders. 
Benign prostatic hyperplasia is the increase in size of the prostate inside its 
capsule, which apply pressure on the urethra, leading to the obstruction to urine 
flow. Benign prostatic hyperplasia is characterized by a slowdown in the urine 
stream build up of urine in the bladder and a frequent  need to urinate. Unlike 
prostate cancer, BPH is not a life-threatening disease, yet, it affects the quality of 
life (QOL). Untreated BPH may lead to urinary retention causing damage to 
kidneys, which may result in renal disease.  
According to WHO, more than 50%males in the 50 plus age groups have 
BPH and the incidence might be as high as 90% at 85 years. worldwide more than 
25 million of elderly men suffer from moderate to severe degree BPH.                                           
Currently available treatment options for the management of BPH include 
medications and surgery.   
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               As per Danvanthri  vaithiyam,  Moothira kirichanam disease is classified 
as 10 types. one such type is Vatha vaththi kirichanam .As per Danvanthri 
vaithiyam,  Vatha vaththi kirichanam is a disease with the symptoms of urinary 
hesitancy, straining, weak urine stream etc..It has the correlation with ‘BENIGN 
PROSTRATE HYPERPLASIA’ of modern science. 
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AIM AND OBJECTIVE 
 
AIM : 
 
To study the efficacy of “SINDHU VALLADHI” (internal) in the treatment of Vatha 
Vaththi Kirichanam (BENIGN PROSTATE HYPERPLASIA) as the above said drug 
formulations has not undergone any clinical trial so far. 
 
OBJECTIVE :  
 
Primary objective :  To evaluate the Siddha drug SINDHU VALLADHI(Internal)  
for  the treatment of Vatha Vaththi Kirichanam (BENIGN PROSTATE 
HYPERPLASIA) 
 
Secondary objective:  To study the siddha cofactors towards  the efficacy of 
medicine. 
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ABSTRACT 
 
 
Benign prostatic  hyperplasia (BPH) occurs in about half of men in their 
50’s and about 90% of men over 85 years of age and affects the quality of life. 
Currently available treatment options for the management of BPH have various 
drawbacks, such as low clinical efficacy and associated adverse results. Because of 
these inadequacy, phytotherapy has been extensively researched and some 
polyherbal formulations have been proven beneficial in the management of BPH. 
Sindhu Valladhi  is a polyherbal formulation recommended for the clinical 
management of BPH and this study was planned to evaluate clinical efficacy and 
safety of Sindhu Valladhi  in BPH. This study was a prospective, preclinical and 
phase II randomized clinical trail and was approved by the “Institutional Ethical 
Committee” 
  A total of 40 patients who were diagnosed as suffering from BPH and who 
were willing to give informed consent were included in the study. Patients with 
acute and chronic prostatitis, prostate carcinoma, neurogenic bladder, bladder 
carcinoma and patients who were put on those drugs, that were likely to affect 
bladder function were excluded from the study. Also patients with severe renal, 
cardiovascular or hepatic disorders, patients indicated for surgery  and those 
patients who were not willing to give informed consent were excluded from the 
study. 
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At the initial casual visit, a comprehensive medical history was obtained 
from all the patients. All the patients underwent a thorough systemic examination . 
Routine biochemical blood tests and specific tests were done for all the patients. 
All the patients were investigated by  USG. 
All the patients  were advised to consume 500mg of Sindhu valladhi  twice 
daily, for a period of 1 months. There was a highly significant reduction in the 
mean IPSS symptom score, in the patients at the end of  treatment. There were no 
significant changes in the hematological and biochemical parameters in the 
patients. This beneficial clinical efficacy of Sindhu valladhi  in BPH might be due 
to the synergistic action of its ingredients. Therefore, it may be concluded that the 
use of Sindhu valladhi  is clinically effective and safe in the management of BPH.  
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
ELUCIDATION ABOUT VATHA VATHTHI KIRICHANAM 
       According to the literature Dhanvanthri Vaithiyam part II “VATHA 
VATHTHI KIRICHANAM”  has been described as: 
                 thjtj;jp fphpr;rdk;; ; ;; ; ;; ; ; 
     “ XJ %j;jpuk; tUk;Ngh ypUf;FNkhh; JsptuhJ 
         kPnjhU Jsp jhd; tPopy; kpFe;j NtjidAz;lhFk; 
      thij fPo;tapW ePh;tha; tUj;jq; fz;bq;Fq; fz;lh 
         aPJjhd; thjtj;jp fphpr;rd nkd;gh; Kd;Ndhh;.” 
                                          ghly; vz;:10; ;; ;; ;  
                                   jd;te;jphp itj;jpak;; ; ; ;; ; ; ;; ; ; ;-ghfk; ;;; - 2 
 
!!!The above quote states that there may be urge to urinate, difficulty in passing 
urine,dribbling ,straining which causes severe pain in the areas such as urethra and 
abdomen. 
   
“XJ%j;jpuk; tUk;Ngh ypUf;FNkhh; JsptuhJ; ; ; ; ;; ; ; ; ;; ; ; ; ; ” 
!!!!!Sensation and fullness of bladder is present but on attempt to micturate/ 
urinate, not even a single drop of urine is expelled out. 
    This line indicates urinary hesistancy. 
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“kPnjhU Jspjhd; tPopy; kpFe;j NtjidAz;lhFk;P ; P ; ; ; ;P ; P ; ; ; ;P ; P ; ; ; ;” 
   Even when a single drop of urine is expelled on straining, it will cause severe 
pain.!
“thij fPo;tapW ePh;tha; tUj;jq; fz;bq;Fq; fz;lhP ; P ; ; ; ; ; ; ; ;P ; P ; ; ; ; ; ; ; ;P ; P ; ; ; ; ; ; ; ; ” 
  Pain present over the lower abdomen and urethral orifice. 
The poem clearly depicts the following symptoms. 
• Urinary hesistancy  
• Retention of urine 
• Straining during urination 
• Pain over lower abdomen and urethra. 
 
In siddha system urinary diseases are classified as, 
• Neer Arugal Noi 
• Neer Perugal Noi 
“ePhpU tpidf; Fzj;ij 
 ePawp tphpj;Jr; nrhy;thk; 
 ePhpidg; ngUf;fnyhd;Nw 
 ePhpidaUf;f nyhd;Nw 
 ePhpop TlNd nfhy;Yk; 
 ePh;f;fl;L tpidfnshd;W” 
. Njud; fhpry;; ;; ;; ; 
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i) Neer Arugal Noi 
The diseases related, when the quantity of urine is suspended for any 
cause. 
ii) Neer Perugal Noi 
The diseases related when the quantity of urine is above the normally 
excreted level due to any cause. 
 Among these, the  “Kiricharam disease” is under the classification of Neer 
Arugal Noi. 
Regarding Moothira Kiricharam the nature of disease, (Ialbu) Noi varum vazhi 
(Etiology) and Noi Vagaipadu  (classifications) have been described in various 
texts. 
 1. Theraiyar Karisal 
 2. Theraiyar venba 
 3. Madhava Nidhanam 
 4. Roga nirnaya saram 
 5. Yugi vaithiya sinthamani 
 6. Mega Noi,Soothga Noi and Arivaiyar Sinthamani 
 7. Jeeva Rakshamirtham 
 8. Sikitcha Rathna theebam 
 9. Anubava vaidhiya Deva Ragasiyam 
10.Pararasa sekaram 
11.Saraga Samhitha 
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 But VATHA VATHTHI KIRICHANAM has been explained only in Dhanvanthri 
Vaithiyam Part II 
 
Synonyms (Veru peyar) 
• Neer churuku 
• Neer Kaduppu 
• Neer Kattu 
Definition (Iyalbu) 
 
According to Theraiyar Karisal 
 
    “ePhpidaUf;fy; vd;Dk; 
 
    ePh;f;fl;bd; Fzj;ijf; Nfl;b 
 
    ePjkpy;yhw; Nfhr 
   
    ePh;g;Gio neUg;Gg; Nghyhk; 
 
    ePgdh Ajj;jhw;gl;l 
 
    ePy tk;gukhq;Ff;fp….” 
!
!
!!!Obstruction of the Urethral passage, causing retention of urine or discharge by 
other unusual ways, urine dribbling out after  micturition. There is also frequently 
sudden stoppage of the stream of urine owing to the contraction of urethra/!
!
According to Theraiyar vagadam 
!
          “%j;jpuf; fphpr;rpf; Fzq;NfsPh; 
 
              KLFe; Jspaha; tpOk; 
 
          Mw;wpj; J}uk; elf;fnthl;lh 
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              jWit kUe;jh yw;WtpLk; 
 
          J}w;wp tpistha; tpise;jpUe;jhy;  
 
             Jilahy; fLfp tpOnkd;W 
 
          khw;wp kWf;f tif fhz 
 
               kDNthh;f; nfy;yh Kiug;gPNu”    -  Njiuah; thlfk; 
!
!The disease is characterized by 
• Dribbling of urine 
• Burning micturition 
• Dysuria 
 
 
According to Pararasa sekaram 
 
         “ rpWeP nuhpe;J JspJspaha;r; 
 
              NrU epwK kQ;rs;fha; 
 
          cWNk rptl;gha; nts;isAkhAthjp 
 
               kpFe;J fLj;J nehe;J 
 
        ngWNk ad;wpg; Gz;zhFk; 
 
             gpd;D kghdq; fLj;JisAk; 
 
        nrWNk nghUKq; fPo; tapW 
 
             NjfnkypAq; fphpr;ruNk;;; ”     
 
. ghuuhr Nrfuk; 
!!!
!
11 
 
The disease is characterized by 
• Voiding small amount of urine 
• Dribbling of urine 
• Yellow colouration of urine 
• Haematuria 
• Dysuria 
• Burning micturition 
• Lower abdominal pain and discomfort 
 
According  to anubava Vaidhiya Deva Ragasiyam, 
   fphpr;ruk; vd;gJ tUj;jj;Jld; nfhQ;fk; nfhQ;rkhf %j;jpuj;ij 
tpor;nra;tJ 
. mDgtitj;jpa ;;;
Njtufrpak;. 
!
Kiricharam refers to dribbling of urine accompanied with pain. 
!
NOI VARUM VAZHI(Etiology) 
!!!!!!!!!“mjpf cl;bzgjhh;j;j krPuz gjhh;j;jhYk; 
         mjpf  rk; Nghfj;jhY kJghd kLf;fyhYk; 
         mjpfd khdt];J cz;bapyLf;fyhYk; 
         mjpf%j;jpu jd;dpw; fphpr;rd kLf;fnkd;d; ; ;; ; ;; ; ; .” 
. jd;te;jphp itj;jpak;; ; ; ;; ; ; ;; ; ; ;     
• Intake of hot and spicy food 
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• Indigested food 
• Alcoholism 
• Excess intake of high calorie food/!
!!
According to Yugi vaithiya sinthamani 
  fUjpNa khg;gz;lq; fjpj;J cz;zy; 
       fhyq;fs; khwpNa kpfg;ngh rpj;jy; 
 gUjpNa gfy;jdpNy ];jphprq; rpj;jy; 
     gfy;jdpNy ghy;nfhs;sy; gfy; cwq;fy; 
 epUjpNa eprpjd;dpw; radQ; nra;jy; 
       epe;ijahk; yhfhpfs; epuk;gTz;zy; 
tUjpNa mf;fpdpapy; rQ;rhpg;Nghh; 
      kfj;jhd fphPr;ruj;jpy; kUT thNuP ; ; ;P ; ; ;P ; ; ; ” 
                                       -a+fp itj;jpa rpe;jhkzp  ; ;; ;; ;  
 
• Intake of carbohydrate rich diet 
• Taking food in untime 
• Daytime sexual indulgence 
• Daytime sleeping 
• Intake of excess narcotics 
• Exposure to high temperature 
 
 
According to Mega Noi, Soothaga Noi, and Arivaiyar Sinthamani 
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!
      “khwhd fphpr;rdk; jhd; ehyjhFk; 
            tUfpd;w tpjkJjhd nrhy;y NfS 
      Ntwhf khg;gz;lk; mjpfk; jpd;why; 
           tpiuthf cw;gdj;jpd; nra;ifahYk; 
      $whf fhyk; khwp cz;lhy; 
           nfhL gfypy; rk;Nghfk; nra;tjhYk; 
      Ntwhf ghjp gfy; jdf;F NkNy 
           ntWk; Mtpd; ghy; cz;Zk; jd;ikahYk; 
          jd;ikAlNd gfy; cwq;Fk; Ngh;f;Fk; 
           jg;ghy; fs;S kpf Fbf;Fk; Ngh;f;Fk; 
     NkdKwNt jP ntf;if jpdKk; nfhz;lhy; 
          Kd;gfypd; #Nlf;f ntapY fha;e;J 
!!!!!!!!!!CdKw rk;Nghfk; mOe;jpr; nra;jy; 
          Cwthf NtrpNaNuhbd;gk; nfhs;sy; 
     VdKw %j;jpu fphpr;rdk; vd;W nrhy;Ny.” 
                                  NkfNeha;> #jfNe;;; ha; kw;Wk;; ; ;; ; ;; ; ; 
 Mhpitah; rpe;jhkzp  ; ;; ;; ;  
!
• Intake of carbohydrate rich diet 
• Taking food in untime 
• Noontime sexual indulgence 
• Daytime sleeping 
• Intake of excess toddy 
• Exposure to high temperature 
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• Intake of hot and spicy food 
• Exposure to forenoon sunlight 
• Abnormal sexual activity 
• Extramaritual sex affair 
 
 According to Jeeva Rakshamirtham 
• Taking food in untime 
• Sleeping in untime 
• Daytime sexual activity 
• Exposure to sunlight 
• Exposure to high temperature 
• Taking narcotics 
 
According to Saraha Samhitha 
• Excessive job stress 
• Taking very efficacious medicine 
• Intake of today 
• Fast running 
• Taking excess non – vegetarian diet 
• Taking undigested food 
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CLASSIFICATION OF MOOTHIRA KIRICHARAM 
 In Dhanvanthiri vaidhiyam, Moothira kiricharam is classified into 10 types. 
!!!!!!!“ mLj;jpLk; thjgpj;j  kUf;fgQ; re;epthje; 
        njhLj;j%j; jpuf;fpue;jp Rf;fpyf;fphprq; fhjk; 
        mLj;j rf;fuNk thjFz;lyp thjtj;jp 
        vLj;jpLq; fphpr;rj;jpd; ngahpit aPiue;jhNk” 
. jd;te;jphp itj;jpak;                ; ; ; ;; ; ; ;; ; ; ;
!!!!!!!!!!!!!!
1. Vaaadha Kirichanam 
2. Pitha Kirichanam 
3. Kaba Kirichanam 
4. Sanni vatha Kirichanam 
5. Moothira kirandhi Kirichanam 
6. Sukila Kirichanam 
7. Moothira kaadha Kirichanam 
8. Sakkara Kirichanam 
9. Vatha kundali Kirichanam 
10. Vatha vaththi Kirichanam 
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In Siddha system various types of Moothira Kiricharam are described in various 
text books. 
I. According to Yogi vaithiya Chindhamani 800 
 
“ njhpaNt fphpr;ruj;jpd; nraiyj; jhDQ; 
    nrg;gNt ehYtifr; rPUkhFk; 
chpaNt thj %j;jp uf;fp upr;ruk; 
    cfg;ghd gpj;j %j;jp uf;fp hpr;rhuk; 
ghpaNt rpNyj;Jk; %j;jp uf;fp hpr;rhuk; 
    ghq;fhd Nkf%j;jp uf;fp hpr;rhuk; 
ehpaNt fphPr;rhue; jhdhy jhFk; 
    ehl;lkha; cw;gj;jp tpyf;fp NfS” 
. A+fp itj;jpa ;;;
rpe;jhkzp 800;;;  
1. Vatha Kiricharam 
2. Pitha Kiricharam 
3. Kaba Kiricharam 
4. Mega Kiricharam 
II. According to Para Rasa Sekaram 
“cw;Nw Njhd;Wq; fphpr;rpe;jh Eiuj;jhh; ehY tifahfr; 
    nrhe;j thj gpj;jfge; njhe;j nkd;guitehYk;” 
. guuhr Nrfuk;;;; 
1. Vatha Kiricharam 
2. Pitha Kiricharam 
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3. Kaba Kiricharam 
4. Thirithoda Kiricharam 
5.  
III. According to Mega noi, Soothara noi and Arivaiyar Sindhaman 
       “nrhy;YNtd; fphpr;rdk; jhd; ehshjpuFk; 
         nrhe;jKWk; thj fphpr;rdk; jhd; xd;W 
      nty;Yk; gpj;j fphpr;rdk; Nrh;g;g fphpr;rdk; 
          tPwhd Nkfj;jpd; fphpr;rdk; jhd; 
      nky;yNt ,it ehY fphpr;rdq;fs; 
           Nkyhd Rj;j KdpNahh;fs; nrhd;dhh;fs; 
      njy;Yfpy; cs;sth;f;F njspthf 
           nfhLj;jpl;Nld; Kd;E}y; Kiwia Ma;e;Nj”   
 
1. Vatha Kiricharam 
2. Pitha Kiricharam 
3. Kaba Kiricharam 
4. Mega  Kiricharam 
 
IV. According to Anuboga Vaithiya Deva Ragasiyam 
1. Vatha moothira  Kiricharam 
2. Pitha moorthira  Kiricharam 
3. Kaba moothira Kiricharam 
4. Thiri thoda  moothira Kiricharam 
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V. According to Jeeva Rakshamirdham 
1. Vatha Kirichara rogam 
2. Pitha Kirichara rogam 
3. Kaba Kirichara rogam 
4. Thiri thoda Kirichara rogam 
VI. According to Sikitcha Rathna Theebam 
1. Vatha Kirichara rogam 
2. Pitha Kirichara rogam 
3. Kaba Kirichara rogam 
4. Thiri thoda Kirichara rogam 
VII. In Roga nirnaya saram  
1. Vatha Kirichara noi 
2. Pitha Kirichara noi 
3. Kaba Kirichara noi 
4. Thiri thoda Kirichara noi 
 
VIII. According to Madhava Nidhanam 
1. Vatha Mootira Kiricharam  
2. Pitha Moothira Kiricharam  
3. Kaba Moothira Kiricharam  
4. Sannipatha Moothira Kiricharam 
5. Koothaja Moothira Kiricharam 
6. Pureeeshaja Moothira Kiricharam 
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7. Acharisha Moothira Kiricharam 
8. Sukkaraja Moothira Kiricharam 
 
XI. According to Saraga sambitha 
2/ thj  Njhlj;jpdhy; Vw;glf;$baJ  - Due to vatham!
3/ gpj;j  Njhlj;jpdhy; Vw;glf;$baJ  - Due to Pitham!
3. fg   Njhlj;jpdhy; Vw;glf;$baJ  - Due to Kabam 
5/ %d;W Njhlj;jpdhy; Vw;glf;$baJ  - Due to Mukkutram!
5. fy;  milg;gpdhy; Vw;glf;$baJ   - Due to Calculi 
7/ kzy; Nghd;w cg;Gfs; NrUtjhy;  ;- Due to deposition!of!
Vw;glf;$baJ!!!!!!!!!!!!!!!!!!!!!!!!!  salts!!
7. tpe;J fl;b jilg;gLtjhy; Vw;glf;$baJ! .Due to deposition  of !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
                                                                                  semen. 
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MODERN ASPECT 
ANATOMY OF PROSTATE GLAND 
 
INTRODUCTION 
 The prostate is a fibromuscular glandular organ of male reproductive 
system, which encircles the male urethra, lies below the neck of urinary bladder. 
Its secretion takes part in the formation of the seminal fluid and corresponds with 
the paraurethral gland of female. 
SITUATION 
1. Below the neck of the urinary bladder. 
2. 2.5 cm behind the lower part of the symphysis pubis. 
3. Above the superior fascia of urogenital diaphragm. 
4. Infront of rectal ampulla. 
5. Between the two levator ani muscles. 
SHAPE 
Conical. 
CONSISTENCY 
 Firm (due to presence of fibromuscular stroma in which glandular tissue are 
embedded). 
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MEASUREMENT 
Length   : 3cm 
 Breadth   : 4cm 
 Thickness   : 2cm 
 Transverse (at the base) : 4cm 
  Weight   : 8gm 
FEATURES WITH RELATIONS 
1. APEX 
i. Direction – Downwards 
ii. Rests on  the superior fascia of urogenital diaphragm. 
2. BASE 
i. Direction – Upwards. 
i. Surrounds the neck of the urinary bladder. 
ii. It is pierced by the urethra on its midline of the junction 
between anterior one-third posterior two-thirds of the gland. 
 
3. SURFACES 
Anterior Surface 
i. The Surface is narrow and convex 
ii. Situated 2cm behind symphysis pubis 
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iii. This surface is separated from the symphysis by the  
a) Retropubic fat 
b) Deep dorsal vein of penis 
c) Prostatic venous plexus 
iv. Attachment of puboprostatic ligaments. 
v. This surface is pierced by the urethra a little above the apex. 
Posterior Surface 
i. This surface is broad and flat 
ii. Shape is triangular. 
iii. The surface is flattened from side to side and convex from 
above downwards. 
iv. This surface is related to the ampulla of rectum separated by 
the rectovesical fascia. 
v. This surface can easily palpated on digital examination 
through the anus which is 4 cm above the anus on its anterior 
aspect 
vi. It is divided into upper smaller and lower larger part by a 
horizontal groove. 
vii. The upper smaller part forms the median lobe 
viii. The lower larger part again divided into two lateral lobes by a 
median sulcus. 
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ix. The horizontal groove close to the median plane is pierced on 
each side by the ejaculatory duct (meeting of the vas 
deference with duct of the seminal vesicle). 
Infero – Lateral Surface   
i. Related with the anterior fibres of the leavator ani. 
ii. Few fibres of the levator ani are blend with the acts as 
levator pro prostate. 
iii. Anterior recess of the ischiorectal fossa situated outside 
the levator ani. 
LOBES 
 It has five lobes : 
1. Anterior. 
2. Posterior. 
3. Median or middle. 
4. Two lateral lobes. 
ANTERIOR LOBE  
i. It lies anterior to the urethra. 
ii. A small part of the gland called isthmus connecting the 
two lateral lobes of the gland. 
iii. The lobe is fibromuscular there is no glandular fissure. 
iv. Adenoma rarely occur. 
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POSTERIOR LOBE 
i.     It lies behind the median lobe and the ejaculatory ducts. 
ii.     It connects the two lateral lobes behind the urethra. 
iii.     Adenoma never occurs, but primary carcinoma may 
begin here. 
MEDIAN OR MIDDLE LOBE 
i. It is bounded: 
Anteriorly by the urethra 
Posterior and on each side ejaculatory ducts. 
Posterior and median plane- prostatic utricle. 
ii. It is wedge shaped. 
iii.      Apex directed downwards towards the colliculus 
seminalis 
iv. It forms the uvula vesicae which is a elevation 
produced by the median lobe in the lower part of the 
trigone of the bladder. 
v. It contains much glandular tissue 
vi. It is the commonest site of adenoma formation. 
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LATERAL LOBES 
i. Lies one on each side of the urethra 
ii. It contains glandular tissue. 
iii. Adenoma may arise. 
STRUCTURES WITHIN THE PROSTATE 
1. PROSTATIC URETHRA 
i. It runs vertically downwards from the base of the 
prostate to    the slightly infront of apex. 
ii. Urethra traverses the gland at the junction of the 
anterior one-third and posterior two-third. 
2. PROSTATIC UTRICLE 
 i. It is ablind sac directed upwards and backwards. 
     ii. 6mm in length. 
iii. Opens at the middle of the urethral crest. 
3. EJACULATORY DUCTS 
i. It passes downwards and forwards posterolateral to the 
median lobe. 
ii. It opens at the colliculus seminalis on each side of the 
prostatic utricle. 
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COVERINGS OF THE PROSTATE 
Inside Outwards 
i. True capsule. It is formed by the condensation of the 
fibrous stroma of the gland. 
ii. False capsule/prostatic sheath. It is formed by the 
visceral layer of pelvic fascia. 
Continuation of the false capsule 
Anteriorly – with  puboprostatic ligaments. 
On eachside – Embedded the prostatic venous plexus. 
Posteriorly- It is avascular and blends with the rectovesical fascia of Denovillier. 
  Between the true and false capsule there lies the prostatic venous 
plexus except at the posterior surfaces. 
NERVE SUPPLY 
Sympathetic nerve. Superior hypogastric plexus. 
Parasympathetic nerve . Pelvic splanchnic nerves derives from S2, S3, S4 Spinal 
segments. 
ARTERY SUPPLY 
i. Inferior vesicle 
ii. Middle rectal 
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iii. Internal pudendal. 
VENOUS DRAINAGE 
i. Veins drains into vesicle plexus finally internal iliac vein. 
ii. Paravertebral veins of Batson. 
LYMPHATIC DRAINAGE   
i. Drians into the internal iliac 
ii. External iliac 
iii. Sacaral groups.  
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BENIGN PROSTATIC HYPERPLASIA 
“When the hair becomes  scanty and grey, when specks of earthy matter begin to 
be deposited in the tunics of the artery and when a white zone is formed at the 
margin of the cornea,  at this same period the prostate gland usually – I might 
perhaps say invariably – becomes increased in size”,  said by Sir Benjamin 
Brodie. 
 BPH involves hyperplasia, which is an increase in the number of cells 
rather than hypertrophy, which is a growth in the size of individual cell. But even 
the urologists use both these words interchangeably. 
 Adenomatous prostatic growth is believed to begin at approximately age 30 
years. An estimated 50% of men have histologic evidence of BPH by age 50 years 
and 75% by age 80 years. in  40–50% of these men, BPH becomes clinically 
significant in 40   -  50% of these men. 
 BPH involves hyperplasia of prostatic stromal and epithelial cells, which 
results in the developement of large and fairly discrete nodules in the periurethral 
region of the prostate. When it is adequately large, the nodules sqeeze the urethral 
canal and cause partial, or  complete barrier of the urethra. This hinders with the 
normal flow of urine, which leads to the symptoms of frequent urination, 
tentativeness in urination,   risk of urinary tract infections, urinary retention and 
dysuria – which means painful urination. While  prostate specific antigen levels 
may be higher in these patients because of inflammation due to urinary tract 
infections and increased organ volume, BPH does not lead to cancer or increase 
the risk of cancer. 
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Epidemiology 
 The prostate gets larger in most men as they get older.  The risk of 
developing BPH for a symptom-free man of 46 years, over the next 30 years is 
45%. The prevelance rates increase from 3 cases per 1000 man-years at age 45 to 
49 years, to 38 cases per 1000 man - years by the age of 75 to 79 years. Whereas 
the prevalence rate is 2.7% for men aged 45–49, it increases to 24% by the age of 
80 years.  
Signs and symptoms 
 The  symptoms  or indications of Benign prostatic hyperplasia are  storage 
symptoms or voiding symptoms.  
Storage symptoms incorporates  
• urinary frequency,  
• urgency incontinence   
• voiding at night - nocturia. 
Voiding symptoms include  
• urinary stream hesitancy,  
• intermittency,  
• dribbling and  
• straining to void. 
 In this case dysuria and pain are not present. 
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 BPH if left untreated ,can be a developing disease. Stasis of bacteria in the 
bladder residue and an increased risk of urinary tract infection are the results of 
incomplete voiding . The crystallization of salts in the residual urine causes the 
formation of urinary bladder stones.. Urinary retention, named chronic or acute  is 
another form of progression. In chronic urinary retention the residual urinary 
volume gradually increases, and the bladder swells, whereas, acute urinary 
retention is the inability to void. Bladder hypotonia is a result of this. Several 
patients who suffer from chronic urinary retention may  ultimately  develop 
obstructive uropathy, which in simple terms may be called  renal failure. 
Cause 
 Most experts consider androgens to play a lenient or progressive role. This 
means that for BPH to occur androgens have to be present, but it does not 
necessarily directly cause the condition. This is strengthened by the fact that 
castrated boys, when they advance in years, do not develop BPH, when they age. 
On the other hand, governing exogenous testosterone is not allied with a 
momentous increase in the hazard of BPH symptoms.  
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Role of Dihydrotestosterone (DHT) 
Dihydrotestosterone , a metabolite of testosterone, is a perilous moderator of 
prostatic growth.  
CIRCULATING TESTOSTERONE 
 
 
5-ALPHA REDUCTASE ACTIVITY IN THE TYPE 2 STROMAL CELLS OF 
PROSTATE 
 
 
DIHYDROTESTOSTERONE 
 
 
AUTOCRINE ACTION                                                 PARACRINE ACTION  
 ON STROMAL CELLS                                                ON EPITHELIAL CELLS 
 
 
 
NUCLEAR RECEPTORS 
 
 
TRANSCRIPTION OF MITOGENIC GROWTH FACTORS IN EPITHELIAL 
AND STROMAL CELLS 
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 DHT is 10 times more persuasive than testosterone because it detaches from 
the androgen receptor very slowly. The significance of DHT in initiating  nodular 
hyperplasia is reinforced by clinical observations in which an inhibitor of 5α-
reductase such as finasteride is given to men with such condition. Therapy with a 
5α-reductase inhibitor evidently reduces the DHT content of the prostate and, 
consequently the prostate volume  is reduced and  in many cases even the  BPH 
symptoms are reduced.   
 Prostate in patients with BPH. A study shows that medical castration 
slashes the serum and prostate hormone levels disproportionately, having less 
effect on dihydrotestosterone and testosterone levels in cell proliferation is 
promoted by Testosterone, but fairly low levels of serum testosterone are found  in 
the prostate. 
 Whereas there is some indication that estrogen may play a vital role in the 
etiology of BPH, this effect appears to be intervened mainly through local 
conversion of androgens to estrogen in the prostate tissue instead of  a direct effect 
of estrogen on its own. In canine, in vivo studies castration, which  reduced 
androgen levels considerably but left the estrogen levels unchanged, and also 
caused substantial atrophy of the prostate. Studies looking for a link between 
prostatic hyperplasia and serum estrogen levels in humans have generally shown 
none.  
 Around the world, on a microscopic level, BPH can be seen in the huge 
difference of men as they age, in pricise over the age of 70 years. However, rates 
of clinically substantial, symptomatic BPH may vary radically depending on 
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lifestyle. Men leading a western lifestyle have a much higher prevalance of 
symptomatic BPH, than men  leading a traditional or rural lifestyle. This is 
confirmed by A research in  
China shows that men living in rural areas have very low rates of clinical BPH, 
while men living in cities who adopt a western lifestyle have a skyrocketing 
incidence of this condition, though it is still below rates seen in the West. 
   
Anatomy  
 
       1= Peripheral Zone,    B = Bladder,                  
                2= Central Zone,    U = Urethra, 
                3= Transitional Zone,   SV = Seminal Vesicle  
                4= Anterior Fibromuscular Zone.   
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According  to the McNeal's model of the prostate, four distinct anatomical 
zones may be distinguished as               
1. The peripheral zone: is the area forming the postero-inferior aspect of the 
gland and represents 70% of the prostatic volume. It is the zone where the 
majority (60-70%) of prostate cancers form. 
2. The central zone: contains the ejaculatory ducts and represents 25% of the 
prostate volume . This  is the zone which normally  gives rise to 
inflammatory processes (eg prostatitis). 
3. The transitional zone: this represents only 5% of the total prostate  
volume. Benign prostatic hypertrophy occurs in this zone and consists of 
two lateral lobes together with periurethral glands. Approximately 25% of 
prostatic adenocarcinomas also occur it this zone. 
4. The anterior zone: predominantly fibromuscular with no glandular 
structures. 
The prostate weighs approximately 20g by the age of 20 and is in  the shape of 
an inverted cone, with the  bladder neck at the base and the apex at the urogenital 
at the diaphragm8.The prostatic urethra does not follow a straight line as it runs 
through the centre of the prostate gland but it is actually bent anteriorly 
approximately 35 degrees at the verumontanum (where the ejaculatory ducts joins 
the prostate) 
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The prostate consists of  epithelial elements and stromal. Fibroblasts, smooth 
muscle cells and endothelial cells are in the stroma and the epithelial cells are  
basal cells, secretory cells and neuroendocrine cells. 
 Both the glandular epithelial cells and the stromal cells (including muscular 
fibers) undergo hyperplasia in BPH. Most sources agree that of the two tissues, 
stromal hyperplasia is predominant, but the accurate ratio of the two is imprecise. 
 Anatomically, BPH is most strongly associated with the posterior urethral 
glands (PUG) and transitional zone (TZ) of the prostate. The initial microscopic 
signs of BPH generally begins between the age of 30 and 50  in the PUG, which 
are posterior to the proximal urethra. However, the majority of growth eventually 
occurs in the TZ. In addition to these two classic areas, the peripheral zone (PZ) of 
the prostate is also involved to a lesser extent. Subsequently prostatic cancer also 
occurs in the PZ. Hence to rule out cancer, BPH nodules in the PZ are often 
biopsied. 
Diagnosis 
Procedures in screening and diagnostic process for BPH. 
Some signs to look for include 
• Weak urinary stream 
• Prolonged emptying of the bladder 
• Abdominal straining 
• Hesitancy 
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• Irregular need to urinate 
• Incomplete bladder emptying 
• Post-urination dribble 
• Irritation during urination 
• Frequent urination 
• Need to urinate during the night  
• Urgency 
•  Involuntary leakage of urine  
• Bladder pain 
• Painful urination 
• Problems in ejaculation 
 The  prostate, testicles and kidneys is often examined through ultrasound 
tests  rule out malignancy and hydronephrosis. 
 Rectal examination that is palpation of the prostate through the rectum may 
reveal a markedly enlarged prostate, usually affecting the middle lobe. 
 Often, blood tests are performed to rule out prostatic malignancy: Elevated 
prostate specific antigen (PSA) levels needs further investigations such as 
reinterpretation of PSA results in terms of PSA free percentage and PSA density, 
and transrectal ultrasonography and rectal examination. These collective measures 
can provide early detection. 
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Management 
Lifestyle 
 Patients should subside the intake of fluid before bedtime. moderate the 
consumption of products containing caffeine and alcohol should be moderate and  
voiding schedules should be followed appropriately. 
Medications 
 5α-reductase inhibitors and alpha blockers  are the two main medications 
for the management of BPH. 
• Alpha blockers: 
In USA and Europe the most common choice for initial therapy are the 
Alpha blockers (technically α1-adrenergic receptor antagonists). 
Doxazosin, terazosin, alfuzosin, tamsulosin, and silodosin are the Alpha 
blockers used for BPH. All the five alpha blockers  are equally effective 
but have slightly different side effect summary. The older drugs 
phenoxybenzamine and prazosin are not recommended. Alpha blockers 
ease smooth muscle in the prostate and the bladder neck, therefore  the 
blockage of urine flow is decreased.  Orthostatic hypotension, 
ejaculation changes, nasal congestion, and weakness are the  common 
side effects of alpha blockers. 
• The 5α-reductase inhibitors: 
 The other treatment option is finasteride and dutasteride of the 5α-
reductase inhibitors. These medications inhibit 5a-reductase, which 
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consequently inhibits production of DHT, which is a hormone that is  
responsible for the  enlarging of prostate. Results or  effects may take a 
longer time  to appear comparing to alpha blockers, but they persevere for 
many years. When this is used together with alpha blockers on patients with 
larger prostates, a reduction of BPH progression to acute urinary retention 
and surgery has been noted.  The Side effects of this are decreased libido 
and ejaculatory or erectile dysfunction.  
 
 Antimuscarinics such as tolterodine may also be used, exceptionally  in 
combination with alpha blockers. Their  action  decreases the  acetylcholine effects 
on the smooth muscle of the bladder, as a result it helps to  control the symptoms 
of an overactive bladder. 
Herbal remedies 
 People often seek herbal remedies for BPH. European countries approve 
several remedies  but  the USA does not approve anything. The  extract of saw 
palmetto from Serenoa repens is one of the most expansively studied. It displayed 
promise in early studies, yet no difference from placebo was indicated by the later 
trials of higher methodological quality. There are no known negative effects of 
saw palmetto, so if the supplement relieves symptoms are taken,  undoubtedly 
there  is a little harm. The quality of saw palmetto products differs considerably. 
 Other herbal medicines that have research support in systematic reviews 
include beta-sitosterol from Hypoxis rooperi (African star grass) and pygeum 
(extracted from  Prunus africana’s bark), while there is less significant support for 
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the efficacy of pumpkin seed (Cucurbita pepo) and stinging nettle root (Urtica 
dioica). There is weak indication that pollen extracts from rye grass (Secale 
cereale) may also correlate with modest symptomatic relief.  
SURGERY 
Prostate surgery may be recommended for patients with  : 
• Recurrent blood in the urine 
• Recurrent urinary tract infections 
• Kidney failure 
• Bladder stones 
The selection of a specific surgical procedure is usually based on the severity of 
your symptoms and the size and shape of your prostate gland. 
• Transurethral resection of the prostate (TURP): This is the most 
common and most proven surgical treatment for BPH.  A scope is inserted 
through the penis to remove the prostate piece by piece in the procedure  of  
TURP. 
• Transurethral incision of the prostate (TUIP): This procedure is quiet 
similar to TURP, but  performed in men who have a smaller prostate. In this 
surgery the patient need not be hospitalized.  Like TURP, a scope is 
inserted till the prostate, through the penis.  Instead of  removing the 
prostate, a small slit is made in the prostate tissue to enlarge the opening of 
the urethra and bladder outlet. 
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• Simple prostatectomy: An open prostatectomy is usually performed using 
spinal or general anesthesia. An incision is made through the abdomen or 
perineum. The inner part of the prostate gland alone is  is removed. The 
outer portion is not disturbed. This is a prolonged procedure, and it 
normally requires a hospital stay of 5 to 10 days. 
 Men who undergo  prostate surgery have considerable improvement in 
urine flow rates and symptoms.   
 Other, less-invasive procedures are also available.  Different forms of heat 
is used in this procedure to destroy prostate tissue. But none has  been proved to be 
better than TURP. Patients who undergo these less-invasive procedures are more 
likely to need surgery again after 5 or 10 years. Yet, these procedures may be an  
option for: 
• Younger men because many of the less-invasive procedures carry a lower 
risk of  incontinence and impotence than TURP, risk with TURP is not 
really  high. 
• Elderly patients 
• Patients with intense medical conditions, such as cirrhosis, uncontrolled 
diabetes, psychosis, alcoholism  and serious  kidney, lung or heart disease. 
• Men who take blood-thinning drugs. 
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SELF-CARE 
For mild symptoms:  
• Urinate when you first get the urge. Also, go to the toilet whenever you 
have the chance, even if you don't feel like urinating. 
• Avoid  caffeine and alcohol, exceptionally  after dinner. 
• Don't take a lot of liquid diet at the same time. Take fluids in equal 
intervals. Avoid drinking  anything  before 2 hours of bedtime. 
• Try NOT to take over-the-counter cold and sinus medications that contain  
antihistamines or  decongestants. Because they  can increase the  symptoms 
of BPH. 
• Keep warm and exercise consistently. Symptoms may worsen due to cold 
weather and lack of physical activity. 
• Learn and carry out  Kegel exercises which are pelvic strengthening 
exercises. 
• Reduce stress. Nervousness and tension can lead to more frequent urination. 
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MATERIALS AND METHODS 
 
Selection of the patients 
 
Forty Male patients between the age group 50 - 90 years suffering from  
Vatha Vaththi Kirichanam were screened and selected. Among them 20 were 
treated as out – patients. Remaining 20 were admitted as in-Patient in the 
department of  P.G. Medicine, Government siddha medicine college and 
hospital, Palayamkottai, After the discharge of in –patients, they were followed 
up as out – patients for some days. Professor, Reader and Asst Lecturer of this 
department   guided and supervised throughout the entire study. 
During this study detailed personal history, relevant past history, 
occupation, habits, clinical symptoms and their duration were obtained from 
each and every patient. 
For this purpose case sheets were prepared based on both siddha and 
modern concepts. They were maintained separately for all cases. 
Investigation  
 With the  help  of Poriyyal  arithal,  Pulanaal  arithal,  Vinaathal,  Mukkutra 
nilaigal, 7  udal kattugal, envagai thervugal investigations were made, 
Simultaneously all the cases were subjected to routine clinical and pathological 
examinations. 
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  IPSS (International Prostate Symptom Score) was carried out before and 
after the treatment. 
Trial Medicine 
 The medicine chosen for this study was Sindhuvalladhi. 500mg twice a day 
with water . 
Reference 
Agathiyar Valladhi 600 
 The trial medicines was prepared in the Post Graduate practical hall, under 
the guidance of staff of the Post Graduate Pothu Maruthuvam Department. 
Evaluation of trial medicines 
 The trail medicines was subjected to Pharmacological analysis at K.M 
College of Pharmacy, Madurai and Biochemical analysis, at the Bio Chemistry  
Laboratory, Govt. Siddha Medical College, Palayamkottai. 
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Results and Observations 
 
 The results were observed with respect to the following criteria by clinical 
study on 20 In-patients and 20 Out-patients. 
 
1. Age Distribution 
2. Kaalam Distribution 
3. Constitution of the body (Thegi ) 
4. Gunam 
5. Religion 
6. Occupational Status 
7. Socio Economic Status 
8. Habits 
9. Dietary Pattern 
10.  Paruva Kaalam 
11.  Thinai Distribution 
12. Weight Distribution 
13.  Clinical Features 
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14.  Associated Symptoms 
15.  Kosangal 
16.   Mukkuttram 
a)  Vatham 
b) Pitham 
c) Kapham 
17.  Ezhu Udalkatthugal 
18.  Envagai Thevugal 
19.  Neerkuri  
20. Neikuri 
21.  Investigations 
22.  Clinical Assessment 
 
 
 
 
 
 
 
 1. Age Distribution
Table  - 1 Illustrates the age distribution and its relative percentage.
 
Sl.No 
 
Age group in 
Years 
1 50-60 
2 61-70 
3 71-80 
4 81-90 
 
 
0
5
10
15
20
25
30
35
40
50-60
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In-Patients Out
No. of 
cases 
Percentage No. of. 
Cases.
1 5 7 
8 40 8 
7 35 4 
4 20 1 
60-70 70-80 80-90
 
-Patients 
 
Percentage 
35 
40 
20 
5 
 
IP
OP
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2. Kaalam 
Table  - 2 Illustrates the Kaalam and its relative percentage. 
 
Sl.No 
 
Kaalam 
In-Patients Out-Patients 
No. of cases Percentage No. of. Cases. Percentage 
1 Vatha Kaalam 
 
- - - - 
2 Pitha Kaalam 
 
5 25 10 50 
3 Kaba Kaalam 
 
15 75 10 50 
 
From the  above study, the maximum number of cases was treated in Pitha  
Kaalam and Kaba kaalam 
 
0
10
20
30
40
50
60
70
80
Vaadha Kaalam Pitha Kaalam Kaba Kaalam
IP
OP
 3. Constitution of the body (Thegi) 
Table  - 3 Illustrates the Constitution of the body  and its relative 
percentage. 
 
Sl.No Constitution of the 
body (Thegi )
1 Vatha thegi
2 Pitha thegi
3 Kaba thegi
4 Thondha thegi
 
0
10
20
30
40
50
60
Vatha Thegi
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In-Patients 
No. of 
cases 
Percentage No. of. 
Cases.
 
- - -
 5 25 4
 11 55 10
 4 20 6
Pitha Thegi Kaba Thegi Thondha Thegi
Out-Patients 
 
Percentage 
 - 
 20 
 50 
 30 
 
IP
OP
 4. Gunam 
Table  - 4 Illustrates the Gunam and its relative percentage.
 
Sl.No 
 
Gunam 
1 Sathuvam 
2 Rajogunam 
3 Thamogunam 
 
In this Patient study, 100 percent cases belongs to Rajogunam.
 
 
0
10
20
30
40
50
60
70
80
90
100
Sathuvam
49 
In-Patients Out
No. of cases Percentage No. of. Cases.
- - - 
20 100 20 
- - - 
 
Rajogunam Thamogunam
 
-Patients 
 Percentage 
- 
100 
- 
 
IP
OP
 5. Religion 
Table  - 5 Illustrates the Religion and its relative percentage.
 
Sl.No 
 
Religion 
No. of cases
1 Hindu 
2 Christian 
3 Muslim 
 
 
0
10
20
30
40
50
60
70
80
90
100
Hindu
50 
In-Patients Out-
 Percentage No. of. Cases.
19 95 18 
1 5 2 
- - - 
Christian Muslim
 
Patients 
 Percentage 
90 
10 
- 
 
IP
OP
 6. Occupational Status 
Table  - 6 Illustrates Occupation  and its relative percentage.
 
Sl.No 
 
Type of work 
1 Farmer 
2 Coolie 
3 Tailor 
4 Driver 
5 Retired Person
 
 
0
10
20
30
40
50
60
70
Farmer
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In-Patients Out
No. of cases Percentage No. of. Cases.
8 40 5 
5 25 - 
2 10 2 
2 10 - 
 3 15 13 
Coolie Tailor Driver Retired 
Person
 
-Patients 
 Percentage 
25 
- 
10 
- 
65 
 
IP
OP
 7. Socio-economic Status
Table  - 7 Illustrates the Socio
 
Sl.No 
 
Socio-economic 
status 
1 High Class 
2 Middle Class
3 Low Class 
  
 
0
10
20
30
40
50
60
70
80
90
High Class
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-economic status  and its relative percentage.
In-Patients Out
No. of 
cases 
Percentage No. of. 
Cases.
- - - 
 3 15 13 
17 85 7 
Middle class Low Class
 
-Patients 
 
Percentage 
- 
65 
35 
 
IP
OP
 8. Habits  
Table  - 8 Illustrates the Habits  and its relative percentage.
 
Sl.No 
 
Habits 
1 Smoker 
2 Tobacco chewer
3 Betelnut chewer
4 Alcoholic 
5 No such habits 
 
 
 
0
5
10
15
20
25
30
35
40
45
50
Smoker Tobacco 
chewer
53 
In-Patients Out
No. of cases Percentage No. of. Cases.
1 5 3 
 1 5 - 
 7 35 - 
3 15 7 
8 40 10 
Betelnut 
chewer
Alcoholic No such 
habits
 
-Patients 
 Percentage 
15 
- 
- 
35 
50 
 
IP
OP
 9. Dietary Pattern 
Table  - 9 Illustrates the Dietary Pattern and its relative percentage.
 
Sl.No 
 
Dietary Pattern 
1 Vegetarian 
2 Mixed diet 
 
 
 
0
10
20
30
40
50
60
70
Vegetarian
54 
 
In-Patients Out
No. of cases Percentage No. of. Cases.
8 40 6 
12 60 14 
 
-Patients 
 Percentage 
30 
70 
 
IP
OP
55 
 
10. Paruva Kaalam 
Table  - 10 Illustrates the Paruva Kaalam  and its relative percentage. 
 
Sl.N
0 
 
Paruva Kaalam 
 
Months 
In-Patients Out-Patients 
No. 
of 
case
s 
Percentag
e 
No. 
of. 
Cases
. 
Percentag
e 
1 
Kaarkaalam 
Aavani, 
purattasi 
14 70 9 45 
2 
Koothirkaalam 
Iyppasi,karthig
ai 
2 10 2 10 
3 Munpanikaalam Markazhi,tai - - - - 
4 Pinpani Kaalam Masi,panguni - - - - 
5 
Elavenil kaalam 
Chithirai,vaika
si 
- - - - 
6 Mudhuvenilkaala
m 
Aani,aadi 4 20 9 45 
 
. 
 
 
 
 11. Thinai  
Table  - 11 Illustrates the Thinai  and its relative percentage.
 
Sl.No 
 
Thinai 
No. of cases
1 Kurinchi 
2 Mullai 
3 Marutham 
4 Neithal 
5 Palai 
 
 
 
0
10
20
30
40
50
60
Kurinji
56 
In-Patients Out
 Percentage No. of. Cases.
4 20 3 
7 35 6 
9 45 11 
- - - 
- - - 
Mullai Marudham Neithal Palai
 
-Patients 
 Percentage 
15 
30 
55 
- 
- 
 
IP
OP
 12. Weight Distribution
Table  - 12 Illustrates the Weight and its relative percentage.
 
Sl.No 
 
Weight 
No. of cases
1 Under wt 
2 Normal 
3 Over wt 
 
. 
 
0
10
20
30
40
50
60
Under wt
57 
 
In-Patients Out-
 Percentage No. of. Cases.
4 20 3 
9 45 12 
7 35 5 
Normal Over wt
 
Patients 
 Percentage 
15 
60 
25 
 
IP
OP
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13. Clinical Features : 
Table  - 13 Illustrates the clinical features  and its relative percentage. 
 
Sl.No 
 
Associated 
Symptoms 
In-Patients Out-Patients 
No. of 
cases 
Percentage No. of. 
Cases 
Percentage 
1  
Incomplete 
Emptying 
(Post void Urination) 
 
14 
 
70 
 
15 
 
75 
2 Intermittency 14 70 18 90 
3 Frequency 17 85 20 100 
4 Urgency 17 85 17 85 
5 Nocturia 18 90 19 95 
6 Straining 
 
11 55 13 65 
7 Weak Stream 
 
20 100 18 90 
  
 
 
 
 14. Associated Symptoms :
Table  - 14 Illustrates the Associated Symptoms  and its relative percentage.
 
Sl.No 
 
Associated Symptoms
1 Cystitis
2 Vesicle Stone
3 UTI 
 
 
 
0
5
10
15
20
25
30
35
Cystitis
59 
 
 
In-Patients Out
No. of 
cases 
Percentage No. of. 
Cases
 3 15 7
 1 5 - 
5 25 5
Vesicle 
Stone
UTI
 
-Patients 
 
Percentage 
 35 
- 
 25 
 
IP
OP
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15. Kosangal : 
Table  - 15 Illustrates the Kosam  and its relative percentage. 
 
SL.NO 
 
Kosangal 
In-Patients Out-Patients 
No. of cases Percentage No. of. Cases Percentage 
1 Annamaya  
Kosam 
- - - - 
2 Pranamaya 
kosam 
- - - - 
3 Manomaya 
kosam 
5 25 7 35 
4 Vignanamaya 
kosam 
5 25 7 35 
5 Ananthamaya 
kosam 
- - - - 
 
 
 
 
 
 
61 
 
16. a.Disturbances in Vatham : 
Table  - 16 Illustrates the disturbance in vatham  and its relative percentage. 
 
Sl.No 
 
Vatham 
In-Patients Out-Patients 
No. of cases Percentage No. of. Cases Percentage 
1 Praanan - - - - 
2 Abaanan 20 100 20 100 
3 Viyaanan - - - - 
4 Udhaanan - - - - 
5 Samanan 20 100 20 100 
6 Naagan - - - - 
7 Koorman 3 15 2 10 
8 Kirukaran - - - - 
9 Devathathan 6 30 4 20 
10 Dhananjeyan - - - - 
. 
 
 
 
 16.b. Disturbances in
Table  - 16(b) Illustrates the disturbances in Pitham  and its relative 
percentage. 
 
Sl.No 
 
Pitham 
1 Analpitham 
2 Ranjagam 
3 Saathagam 
4 Praasagam 
5 Aalosagam 
 
. 
0
10
20
30
40
50
60
70
80
90
Analpitham Ranjagam
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 Pitham  : 
In-Patients Out
No. of cases Percentage No. of. Cases
- - - 
- - - 
18 90 15 
- - - 
3 15 2 
Saathagam Praasagam Aalosagam
-Patients 
 Percentage 
- 
- 
75 
- 
10 
 
IP
OP
 16.c. Disturbances in Kapham  :
Table  - 16(c) Illustrates the Kapham  and its relative percentage.
 
Sl.No 
 
Kapham 
1 Avalambagam 
2 Kilaethagam 
3 Pothagam 
4 Tharpagam 
5 Santhigam 
.
 
 
0
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25
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40
45
Avalambagam
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In-Patients Out
No. of cases Percentage No. of. Cases
- - - 
- - - 
- - - 
- - - 
9 45 6 
Pothagam Santhigam
 
-Patients 
 Percentage 
- 
- 
- 
- 
30 
 
IP
OP
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17. Involvement of Ezhu Udalkattugal : 
Table  - 17 Illustrates the involvement of ezhu Udalkattugal  and its relative 
percentage. 
 
Sl.No 
 
Udalkattugal 
 
In-Patients Out-Patients 
No. of 
cases 
Percentage No. of. 
Cases 
Percentage 
1 Saaram [Chyme] 20 100 20 100 
2 Senneer [Blood] 7 35 5 25 
3 Oon [Muscle] - - - - 
4 Kozhuppu [Fat] 9 45 6 30 
5 Enbu [Bones] 9 45 6 30 
6 Moolai [Bone 
marrow] 
- - - - 
7 Sukkilam [Genital 
discharges] 
- - - - 
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18. Envagai Thervugal : 
Table  - 18 Illustrates the Condition of envagai Thervugal  and its relative 
percentage. 
 
Sl.No 
 
Envagai Thervugal 
In-Patients Out-Patients 
No. of cases Percentage No. of. Cases Percentage 
1 Naa - - - - 
2 Niram - - - - 
3 Mozhi - - - - 
4 Vizhi - - - - 
5 Malam - - - - 
6 Moothiram 20 100 20 100 
7 Sparisam - - - - 
8 Naadi     
 a) Vatha pitham 10 50 6 30 
 b)  Vatham kabam 1 5 3 15 
 c) Pitham vatham 6 30 8 40 
 d) Pitham kabam - - - - 
 e)Kaba vatham 3 15 3 15 
 f) Kaba pitham - - - - 
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19. Neerkuri  : 
 
 
Sl.No 
 
Type of test result 
 
In-Patients Out-Patients 
No. of 
cases 
Percentage No. of. 
Cases 
Percentage 
1 Niram 8 40 5 25 
2 Manam 12 60 15 75 
3 Edai - - - - 
4 Nurai 3 15 7 35 
5 Enjal - - - - 
 
20. Neikuri  : 
 
Sl.No 
 
Type of test result 
 
In-Patients Out-Patients 
No. of 
cases 
Percentage No. of. 
Cases 
Percentage 
1 Vatha neer 8 40 9 45 
2 Pitha neer 7 35 6 30 
3 Kaba neer 5 25 5 25 
 
 22. Assessment of Result :
Table  - 22 Illustrates the Assessment of Result  and its relative percentage.
 
Sl.No 
 
Result 
1 Good Response
2 Moderate 
Response(Fair)
3 Poor Response
 
  
0
10
20
30
40
50
60
70
80
90
100
Good Response
67 
  
In-Patients Out
No. of 
cases 
Percentage No. of. 
Cases
 19 95 18
 
1 5 2 
 - - - 
 
Moderate 
Response (Fair)
Poor Response
 
-Patients 
 
Percentage 
 90 
10 
- 
 
IP
OP
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DISCUSSION 
  
 Efficacy of siddha system in curing the vatha vaththi kirichanam prompted 
me to carry out clinical and scientific study in this disease.   For this clinical trail 20  
patients were selected and admitted as In-patients in  Post Graduate Department 
of Pothu Marthuvam and were treated with the trial  medicine.  After  discharge  
all  the  twenty  patients  were  followed  as  the  Out patients.  
  The  medicine  was  also  trialed  with  20  Out-patients  in  the                         
Out-patients Department of Pothu Maruthuvam.  
  The results were clearly observed and recorded under the supervision of 
Professor, Reader and Assistant lecturer. The observed results were discussed  
here.  
  
1. Age Distribution  
  Among the In-patients 5% of the patients were affected in the age groups 
of 50-60 years, 40 % of the patients were affected in the  age group of 61-70 
years,  35% of the patients were affected in the age group of 71 – 80. 20% of the 
patients were affected in the age group of  81- 90 years.  
  Among  the  Out-patients  35%  of  the  patients  were  affected  in  the  
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age group of 50-60 years and 40% of each of the patients were affected in the age 
group of 61-70 years and 20% of each of the patients were affected in the age 
group of 71-80 years, 5% of the patients were affected in the age group of 81-90.  
  So the occurrence of the disease was found in male patients above 50 
years 
2. Kaalam Distribution  
  Among the In - Patients 25% were affected in Pitha Kaalam and 75% were 
affected in Kaba Kaalam.  Among the Out - Patients 50 % were affected in Pitha 
Kaalam and 50 % were affected in Kaba Kaalam. 
 The  table  showed  the  increased  incidence  of  the  disease  in  the  Pitha 
Kaalam  and  kaba kaalam 
3.Thegi Distribution 
 25% of the In-patients and 20% of the Out-patients were pitha thegi.  55% 
of the In-patients and 50% of the Out-patients were kaba thegi and 20% of the In-
patients and 30% of the Out-patients were thondha thegi. 
4. Gunam Distribution  
Among the In – Patients and out-patients, 100% had rajogunam 
5. Religion Distribution  
           Among the In-Patients 95% were Hindus, 5% were Christians.  Among the 
Out-Patients 90% were Hindus, 10% were Christians, 15% were Muslims. 
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 6. Occupational Status 
 Among the In-Patients  40% were farmers,25% were Coolie,10% 
were Tailors,10% were Drivers and 15% were Retired Persons. 
 Among the Out-Patients 25% were farmers ,10% were Tailors and 
65% were Retired Persons. 
7.Socio Economic status 
 Among the In-Patients  85% were lower class and 15% were middle 
class. 
 Among the Out-Patients  35% were lower class and 65% were 
middle class. 
8. Habits  
  Among  the  In-patients  5%  of  the  patients  were  smokers, 5%  of the 
patients were tobacco chewers,35%  of the patients were betel nut chewers, 15% 
of the patients were alcoholics and Other 40% had no such habits.  
  Among  the  Out-patients  15%  of  the  patients  were  smokers, 35% of 
the patients were alcoholics and Other 50% had no such habits.  
 
 9. Diet  
  Among the In-patients 60% of the patients had mixed diet and 40% had  
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vegetarian diet. Among the Out-patients,  70% of the patients had mixed diet and 
30% had  vegetarian diet. 
10.Paruva Kaalam Distribution  
  Among the In-patients 70% of the incidence of the disease fall under the 
Kaar Kaalam i.e. Avani & Purattasi (August & September)  10%  of  the  incidence  
fall  under  the  Koothir  Kaalam  i.e.  Iypasi  &  Karthigai  (October  &  November).  
20%  of  the  incidence  fall  under  the MudhuvenilKaalam  that is the  Aani & 
Aadi  (June & July)  
  Among  the  Out-patients  45%  of  the  incidence  fall  under  the Kaar 
Kaalam i.e. Aavani &  Purattasi (August & September) 10%  of  the  incidence  fall  
under  the  Koothir  Kaalam  i.e.  Iypasi  &  Karthigai  (October  & November) and 
45% each of  the incidence fall under the Muthuvenil Kaalam i.e. Aani & Aadi 
(June & July) 
11. Thinai Distribution  
  Among the In-patients 45% belonged to the Marutham  and 35% belonged 
to the Mullai and 20%  belonged to the kurunchi. 
  Among  the  Out-patients,  55%  belonged  to  the  Marutham  and 30% 
belonged to the Mullai and 15% belongs to the kurunchi. 
   
. 
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12. Weight Distribution  
  Among the In-patients 20% were under weight, 45% were normal weight 
and 35% were  over weight.. 
  Among  the  Out-patients  15% were under weight, 60% were normal 
weight and 25% were over weight. 
13. Distribution of Clinical Features  
  The data from the observation showed that   
  Incomplete Emptying was present in 70% of the In-patients and 75% of the            
Out-patients.  Intermittency  was  present  in  70%  of  the  In-patients  and  90%  
of  the  Out-patients. Frequency was present in 85% of the In-patients and 100% 
of the Out-patients. Urgency was present in 85% of the In-patients and 85% of 
the            Out-patients.  Nocturia  was  present  in  90%  of  the  In-patients  and  
95%  of  the  Out-patients. Straining  was present in 55% of the In-patients and 
65% of the Out-patients. Weak stream  was present in 100% of the In-patients 
and 90% of the Out-patients. 
14.  Associated symptoms 
  Among  the  In-patients  15%  of  the  patients  were  affected with cystitis,  
5%  of  the  patients  had  the  bladder stone and 25% of the patients were 
affected with UTI. 
  Among  the  Out-patients  35%  of  the  patients  were  affected with 
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cystitis and  25% of the patients were affected with UTI. 
15. Kosangal  
     Manomaya kosam affected in  25% and Vingyana maya kosam was 
affected in  25% of In-patients. . 
  Manomaya kosam affected in 35% and Vingyana maya kosam was affected 
in 35% of Out-patients. 
16. Mukkutram      a. Vatham  b.Pitham  c. Kabam  
 a. Vatham  
   Abanan and samanan were  affected  in  100%  of    In-patients  and  Out-
patients.  Devathathan was affected  in  30%  of  the  In-patients,  and 20% of the 
Out-patients. Koorman was affected in 15% of the     In-patients, and 10% of the 
Out-patients.  
 .  Abanan is resposible for excretion of urine and motion. This vayu was 
affected in this disease. 
  Samanan is responsible for controlling other vayus. Since samanan cannot 
control other vayus, it affected in this discase,  
  Koorman is responsible for vision. In the clinical trial this vayu was affected 
due to aging.  
  Devathathan  is  responsible  for  tiredness  after  sleep  and  emotion.   
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b. Pitham  
   Sadhaga  pitham  was  affected  in  90%  of  the  In-patients  and  75%  of  
the  Out-patients. Aalosaga  pitham  was  affected  in  15%  of  the  In-patients  
and  10%  of  the  Out-patients. 
 c. Kabam  
 Sandhigam  was  affected  in  45%  of  the  In-patients  and  30%  of  the 
Out-patients.  
  Sandhigam resides in the joints and helps for movement.  Since, there was 
Joint pain, it was affected. It was may be due to their aging.  
 
 17. Ezhu udal kattugal  
  In  Ezhu  udal  kattugal,  saaram  was  affected  in 100%  of  the                    
In-patients and Out-patients. Enbu and Kozhuppu were affected in 45% of the                    
In-patients and 35% of the Out-patients.  Senner was affected in 35% of the                      
In-patients and 25% of the Out-patients.  
  Enbu and Kozhuppu are responsible for the movements of the body and 
gives  lubrication  to  the  joint  cavities.  Since, there  was  joint  pain,  these  two  
were affected may be due to aging.  
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18. En vagai thervugal  
  In Naadi, 50% of the In-patients and 30% of the Out-patients had vatha  
pitha naadi. 5% of the In-patients and 15% of the out- patients had vatha kaba 
naadi.  30%  of  the  In-patients  and  40%  of  the  Out-patients  had  pitha  vatha 
naadi. 15% of the In-patients and 15% of the Out-patients had kaba vatha naadi. 
19. Neerkuri  
  Manam was affected in 60% of In-patients  and 75% of the Out-patients. 
Niram was affected in 45% of In-patients  and 25% of the Out-patients. Nurai was 
affected in 15% of In-patients  and 35% of the Out-patients. 
 
20. Neikuri  
  In  Neikuri 40% of the In-patients and 45% of the Out- patients had vatha 
neer, 35% of the In-patients and 30% of the Out patients had pitha neer and 25% 
of the In-patients and 25% of the Out patients had kaba neer 
 21. Laboratory Investigations : 
  Routine  investigations  of  blood  and  urine  were  done  during  the  
admission and at the end of the treatment for all cases.  
  Before treatment Ultra sonography study was taken in all Out-patients  
and In-patients and PSA study is taken to rule out Ca prostate. 
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After treatment Ultra sonography report showed decrease in the size, 
volume of the prostate and residual Urine. So it proves that the trial drug was 
reduced BPH. 
22.Clinical Assessment: 
  Among the In-patients 95% were showed good response and 5% showed 
Moderate response. 
Among the Out-patients 90% were showed good response and 10% showed 
Moderate response. 
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SUMMARY 
  Vatha vaththi kirichanam (Benign Prostate Hyperplasia) is a disease which 
affect quality of life among the geriatric population, this disease has the 
correlation with Benign prostatic hyperplasia of modern science. 
 The most common symptoms are urinary frequency, urgency, 
intermittency, nocturia, weak stream, straining and incomplete emptying of the 
bladder.   
For this clinical study 20  male patients of age above 50 groups were 
selected  and admitted as In-patients in Post Graduate Department of Pothu 
Maruthuvam. After the discharge all the 20 patients were followed as out 
patients. 
20 out-patients were selected  and treated in Out-patients Department of  
PG Pothu Maruthuvam 
  Sindhu valladhi( 500mg twice daily after meal) was taken as trail medicine 
for this dissertation work. 
 The results of this clinical trial were found to be very encouraging in 
almost every cases. There was marked improvement within few days of 
treatment.  
 There were no clinical side effects, toxic effects during the course of 
treatment. 
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 My trial drug when experimented on patients who had both BPH and 
renal calculus, renal calculus has completely cured. 
 Anti microbial study showed that the trial drug Sindhu Valladhi was 
sensitive against Pseudomonas aeruginosa and moderately sensitive 
against  Streptococcus pneumonia and Escherichia coli. 
 Bio chemical analysis showed that the given sample of Sindhu Valladhi 
contains chloride, ferrous iron, unsaturated compound and reducing 
sugar. 
 Pharmacological analysis showed that the trial drug, Sindhu valladhi  has 
significant Antiandrogenic activity. 
 Clinically 95% of the patients showed good results. 
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CONCLUSION 
 
 In this pre clinical and randomized phase II trial, the results were 
found to be good in 95% of IP cases, 90% of OP cases, fair in 5% of 
IP cases and 10% of Op cases. 
 
 Clinically the trial medicine was very effective to the suffering 
patients and relieved  the symptoms. 
 
 Further follow up of all these patients showed efficacy of medicine. 
 
 Clinical study showed no adverse effects of trial medicine during the 
study. 
 
 Uses of Sindhu Valladhi is clinically effective and safe in the 
management of BPH. 
 
 It is concluded that Vatha Vaththi Kirichanam is controlled by the 
drug Sindhu Valladhi (500mg-BD). 
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PREPARATIONS AND PROPERTIES OF THE TRIAL MEDICINE 
 
 
PREPARATIONS OF TRIAL MEDICINE 
 
 rpe;J ty;yhjp; ;; ;; ;  
 
     epidthd gok;Gspjhd; gyNkh ehd;F 
           epiwaNt Nrq;nfhl;il gye;jhd; ehd;F 
     fdkhd KUf;fpiyapy; J}S%d;W 
           fl;lhd fwpAg;G gyNkh nuz;L 
     jdkhd ntq;fhuk; gyK nkhd;W 
          jg;ghNj ntbAg;G ,uz;L jhDk; 
     rpdkhf cuypypb ikdk; NghNy 
          jpul;bNa Rz;ilf;fha; msT nfhs;Ns 
     nfhs;sNt ePuilg;G gTj;jpu #iy 
          FbnfLj;j fy;yilg;Gf; Fd;k thA 
     nks;sNt Fly;gLtd; mz;l thA 
          tpopyhd jirailg;G cjpu thA 
     fps;sNt kiwe;jpUe;j ngUePh;f; Nfhit  
          Nfl;Fklh fhe;jj;ijr; Nrh;j;Jf; nfhs;S 
     Js;sNt te;jNeha; njhiye;J NghFk; 
          Re;jhpf;F <rdd;W nrhd;dthNw 
 
- mfj;jpah; ty;yhjp ; ; ;; ; ;; ; ; -
600 
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gok;Gsp  - 4 gyk; 
Nrq;nfhl;il - 4 gyk;        
KUf;fpiy nghb - 3 gyk;  
fwpAg;G  - 2 gyk; 
ntbAg;G  - 2 gyk; 
ntq;fhuk;  - 1 gyk; 
 
 
    Mfpatw;iw cuypypl;L ed;whf ,bj;J nkOF gjj;jpy;  vLj;J 
itj;Jf; nfhs;s Ntz;Lk;. 
 
msT  : Rz;ilf;fha; 
 
jPUk; Neha;fs;  : jirailg;G> ePuilg;G> gTj;jpuk;> #iy> 
fy;yilg;G> Fd;kthA> Fly;gLtd;> mz;lthA> > cjputhA> 
ngUePh;f;Nfhit.    
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PROPERTIES OF THE TRIAL MEDICINE 
 
 
1.SINDHU VALLADHI : 
 
INGREDIENTS: 
 
1. gok;Gsp (Palampuli) 
2. Nrq;nfhl;il (Sengrangkottai) 
3. KUf;fpiy nghb(Murukilli podi) 
4. fwpAg;G(Kariuppu) 
5. ntbAg;G(Vediuppu) 
6. ntq;fhuk;(Vengaram)    
 
 
Palam Puli 
 
 
Botanical Name : Tamarindus indica 
English Name : Tamarind 
Family  : Caesalpinioideae 
Part Used  : Fruit 
Suvai  : Pulipu 
Thanmai  : Veppam 
Pirivu  : Karppu 
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  jPjpy; gok;Gspiar; Nrh;f;fj; jphpNjhlk; 
     thjnkhL #iyfgk; khWq;fhz;-XJRuQ; 
     rh;j;jpnad;w Njhlkpit rhe;jkhq; fz;Nzha;Nghk; 
     gpj;jnkd;w NgnuhopAk; NgR.  
                               -mfj;jpah; Fzthflk; ;; ;; ; ; 
 
 
Action : Mukkutram, Vazhinoi, Soolai, Iyyaperukku, Kannoi,        
Pitham. 
 
Sengkottai 
 
Botanical Name : Semecarpus anacardium 
English   Name : Marking Nut, Oriental cashew 
Family  : Anacardiaceae 
Part Used  : Nut 
 
Suvai  : Kaippu,Verruvrupu 
Thanmai  : Veppam 
Pirivu  : Karppu 
Chemical Constituents :  
Flavonoids- Semecarpetin, nallaflavone, galluflavanone, 
tetrahydroarmentoflavone. 
Fixed oil- stearic,palmitic, linoleic oleic and arachidic acids.  
It has antineoplastic activity, immunomodulatory activity and 
hypocholesterolaemic activity 
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Murukilai podi 
 
Botanical Name : Erythrina variegata 
English   Name : Indian coral tree 
Family  : Fabaceae 
Part Used  : Leaf 
Suvai  : Kaippu,Karppu 
Thanmai  : Veppam 
Pirivu  : Karppu 
Action  : Diuretic, Laxative,  Emmenagogue 
 
Kariuppu 
 
Botanical Name :  
English   Name : Sodium chloride,Common salt 
Suvai    : Karipu 
 “ ke;jk; nghUkyWk; thATk;Nghk;jPgdkhk; 
   njhe;jpj;j [ae; njhlUNkh- re;jjKk; 
   mf;fpdpapd; G~;b mlUq; fwpAg;ghy; 
   rpf;Ffpd;w ePhpwq;FQ; nrg;G” 
(ngh-s;) fwpAg;ghy; ke;jk;>tapw;Wg; nghUky;>thA>fgk; 
ePq;Fk;.ePuilg;G jPUk;.grpAk; rkhf;fpdpAk; mjpfg;gLk; 
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Vediuppu 
English   Name : Potassium Nitrate 
 
“ ky;yhU kl;lFd;k khjUj uj;jf;fl;b 
  fy;yh kijg;GePh;f; fl;lUf-nyy;yhNk 
  fk;gpfk;gp nad;Wq; fUTz;lh kq;fpepd;w 
  fk;gpfk;gp nad;Wiuf;Fq; fhy;” 
 
(ngh-s;) %j;jpufphpr;ruk;>ePh;r;RUf;F>vz;tpj Fd;kk;> fUg;ghahrf; 
fl;b>Nrhig jPUk;. 
 
Vengaram 
    
English Name : Borax 
   Suvai  : Inippu,Thuvarppu 
   Verium  :Veppam 
    
   “ nrhwpGilnaz; Fd;keik Nrhhp ahrk; 
    gwpfpufzp fy;Y}dk; gd;Ndha;-newpiaj; 
    jlq;fzq;f gq;fpUkp rh;g;gtplQ; re;ep 
    aplq;fzq;f yf;fpw;Ngh nkz;” 
 
 
(ngh-s;)  ntq;fhuj;jpdhy;> %j;jpufphpr;ruk;> m];khhp> jtisr;nrhwp> 
vz;tif Fd;kk;> ,uj;j %yk;> xOf;Ff; fpufzp Kjypa Neha;fs; 
jPUk;.  
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BIOCHEMICAL ANALYSIS OF SINDHU VALLADHI 
PREPARATION OF THE EXTRACT 
       5 grams of the drug is weighed accurately and placed in a 250 ml clean 
beaker. Then 50 ml of distilled water is added and dissolved well. Then it is boiled 
well for about 10 minutes. It is cooled and filtered in a 100 ml volumetric flask and 
then it is made up to 100 ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S. 
NO 
EXPERIMENT OBSERVATION INFERENCE 
1 TEST FOR CALCIUM 
2 ml of the above extract is 
taken in a clean test tube. 
To this add 2 ml of 4% 
ammonium oxalate solution 
 
A white precipitate is 
formed 
 
Absence of 
calcium 
2 TEST FOR SULPHATE 
2 ml of the above extract is 
added to 5% barium 
chloride solution 
 
 
No white precipitate is 
formed 
 
Absence of 
sulphate 
 
3 TEST FOR CHLORIDE 
The extract is treated with 
silver nitrate solution 
 
A white precipitate is 
formed 
 
Presence of 
chloride 
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4 TEST FOR 
CARBONATE 
The substance is treated 
with concentrated HCL 
 
No brisk effervescence 
is formed 
 
Absence of 
carbonate 
5 TEST FOR STARCH 
The extract is added with 
weak iodine solution 
 
No blue color is 
formed 
 
Absence of starch 
6 TEST FOR FERRIC 
IRON 
The extract is acidified with 
glacial acetic acid and add 
potassium ferrocyanide 
 
No blue colur is 
formed 
 
Absence of ferric 
iron 
7 TEST FOR FERROUS 
IRON 
The extract is treated with 
concentrated nitric acid and 
ammonium thio cyanate 
solution 
 
Blood red colour is 
formed 
 
Indicates 
presence of 
ferrous iron 
8 TEST FOR PHOSPHATE 
The extract is treated with 
ammonium molybdate and 
concentrated nitric acid 
 
 
No yellow precipitate 
is formed 
 
Absence of 
phosphate 
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9 TEST FOR ALBUMIN 
The extract is treated with 
Esbatch’s reagent 
 
No yellow precipitate 
is formed 
 
Absence of 
albumin 
10 TEST FOR TANNIC 
ACID 
The extract is treated with 
ferric chloride 
 
No blue black 
precipitate is formed 
 
Absence of tannic 
acid 
11 TEST FOR 
UNSATURATION 
Potassium permanganate 
solution is added to the 
extract 
 
It gets decolourised 
 
Indicates the 
presence of 
unsaturated 
compound 
12 TEST FOR REDUCING 
SUGAR 
5 ml of benedict’s 
qualitative solution is taken 
in a test tube and allowed to 
boil for 2 minutes and add 
8- 10 drops of the extract 
and again boil for 2 minutes 
 
 
 
Colour change occurs 
 
 
Indicates the 
presence of 
reducing sugar 
13 TEST FOR AMINO 
ACID 
 
No violet colour is 
 
Absence of 
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One or two drops of the 
extract is placed on a filter 
paper and dried well. After 
drying 1% Ninhydrin is 
sprayed over the same and 
dried well 
formed amino acid 
14 TEST FOR ZINC 
The extract is treated with 
potassium ferrocyanide 
 
No white precipitate is 
formed 
 
Absence of zinc 
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ANTI-ANDROGENIC ACTIVITIES OF SINDHU 
VALLADHI 
INTRODUCTION 
Nowadays, androgen-mediated diseases such as prostate cancer, hirsutism, 
acne, androgenic alopecia and benign prostatic hyperplasia (BPH) have become 
serious problems(Barrtsch et al., 2002). Above all, BPH is one of the most 
common ailments seen in older men; 40% of men 50–60 years of age and 90% of 
men 80–90 years of age have been diagnosed with BPH. The principal prostatic 
androgen is dihydrotestosterone (DHT), which is formed by the steroidenzyme 5α-
reductase from its substrate testosterone (Russell and Wilson, 1994). 5α-Reductase 
is a membrane-bound NADPH-dependent enzyme that catalyzes the reduction of 
testosterone to the more potent androgen DHT. The effect of DHT is purely 
androgenic in that, unlike T, it cannot be transformed into estrogen. Since the 
weight of the seminal vesicles depends on the 5α-reduced androgens, it is 
important to regulate the level of the DHT. Therefore, 5α-reductase inhibitory 
ingredients should be useful in the treatment of BPH (Barrtsch et al., 2000). 
Two isoforms of 5α-reductase (types 1 and 2) have been cloned, expressed 
and characterized; they display different tissue expression patterns, enzyme kinetic 
parameters and chromosomal localization (Jenkins et al., 1991). These two 5α-
reductase isozymes have been identified in both rats and humans, and both 
isozymes are over-expressed in BPH tissue(Iehle et al., 1999). Coded by two 
different genes (Andersson and Russell, 1990), they display a maximal activity at 
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different pH (6.5 for type 1 and 4.5 for type 2); overall, they have different 
biochemical characteristics. In rats, the type 1isozyme predominates in tissues such 
as liver, kidney, brain, lung, and skin but also exists in the prostate, whereas the 
type 2 isozyme is more abundant in genital tissues such as the prostate. A number 
of synthesized 5α-reductase inhibitors with steroidal moiety have been reported.  
However, it should be noted that these inhibitors have the potential to cause 
adverse effects such as those reported for finasteride (Uygur et al., 1998) i.e., 
gynecomastia, impairment of muscle growth, and severe myopathy due to their 
structural similarity to steroidal hormones. Hence, the emergence of therapeutic 
materials having fewer side effects preferably, natural products would be highly 
desirable if their safety could be guaranteed.Although there is no clear evidence 
that patients who develop BPH will ultimately have prostate cancer, androgens do 
influence the development of prostate cancer (Rosset al., 1992; Giovannucci et al., 
1997; Hsing et al., 2002). The use of finasteride, the 5α-reductase inhibitor, can 
lower the androgen levels in the prostate and reduce the risk of prostate cancer 
(Thompson etal.,2003). 5α-reductase inhibition and suppression of androgen-
induced prostate cell growth by sindhu valladhi  have never been reported. In this 
paper, we have demonstrated the in vitro and in vivo anti-androgenic activity of 
sindhu valladhi for the first time.  
 Materials and methods 
This research was conducted in accordance with institutional animal ethical 
committee for laboratory animal use and care as found in, for example, CPCSEA 
guidelines. 
92 
 
 
 Materials 
Chemicals were obtained from Sigma Aldrich Co. Ltd. (USA).Organic 
solvents were purchased from S.D.Fine Pure Chemical Industries Co. (Mumbai). 
Testosterone was obtained from PerkinElmer  Co. Ltd. (USA).Sprague–Dawley 
(SD) rats were obtained from kings instute,Chennai. 
 
Preparation of rat microsomes  
Rat liver and prostate microsomes from female (7 weeks age) and male (13 
weeks age) SD rats, respectively, were prepared by a method previously reported 
by Shimizu et al.(2000) with some modifications. Two mature SD female rats were 
killed. Their livers were removed and minced tissue was homogenized in four 
tissue volumes of medium A (0.32M sucrose, 1mM dithiothreitol, and 20mM 
sodium phosphate,pH 6.5). Also, three mature male SD rats were killed. Their 
prostates were removed and minced tissues were homogenized in four tissue 
volumes of medium A.  
The homogenate was then centrifuged at 10,000×g for 10 min. The 
resulting supernatant from the centrifugations was further centrifuged at 15,000×g 
for 1 h twice. The washed microsomes were suspended in one pellet volume of 
medium A, and the dispersion of microsomes was achieved using a syringe with 
18G, 23G, and 26G needles in succession. The microsome suspension was stored 
at −20 ◦C just before use. 
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Measurement of 5α-reductase inhibitory activity 
A complete reaction mixture included 1mM dithiothreitol, 20mMphosphate 
buffer (pH 6.5 for 5α-R1 or pH 5.0 for 5α-R2), 1.9 nCi [4-14C] testosterone, 
150µM testosterone,167 µM  NADPH, and the enzyme preparation (1.54 mg of 
protein) in a final volume of 0.3 ml. The concentration of testosterone contributed 
by [4-14C] testosterone was negligible.Sindhu valladhi at room temperature,were 
added to the solution at a concentration of 200 ppm. The incubation of these 
samples was carried out for 10 min at 37 ◦C and was started by the addition of 10 
µl microsomes to the pre-heated reaction solution in a tube. After l0 min,the 
incubation was terminated by adding 10 µl  of 3M NaOH. To extract the 
metabolites, lml of diethyl ether was added, and the tubes were capped and shaken. 
The organic phase was applied to a silica plate (Kieselgel 60 F254). The plate was 
developed in ethyl acetate-n-hexane (7:3) at room temperature. The radioactivity 
profile was determined with an imaging analyzer (FLA-5000 RF, Fuji Film Co. 
Ltd.,Tokyo, Japan). The 5α-reductase activity was calculated from the percentage 
conversion of [4-14C] testosterone to [4-14C] dihydrotestosterone. 
 
Growth suppression of the rat prostate by sindhu valladhi 
The assay for growth suppression of the rat prostate was performed as 
described by Fukuta et al. (1999). The testes of SD rats were removed at 4 weeks 
of age under light anesthesia with pentobarbital. After 4 days, testosterone (100 
µg/body) was injected s.c. into the rats once daily for 7 days. Sindhu valladhi were 
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orally administered at concentrations of 50 mg/kg of body weight once daily for 7 
days. Flutamide (10 mg/kg body weight) was used as the positive control and was 
suspended in 0.5% methylcellulose and orally administered once daily for 7 days. 
After 7 days, rats were deprived of food and water for 18 h and sacrificed by 
pentobarbital. Then, their prostates were removed and their weights determined. 
Statistics 
Results were expressed as mean±S.E.M. Statistical significance was 
determined by ONE WAY ANOVA followed by Newmann keul’s multiple range 
tests. 
 Results 
 
 5α-Reductase inhibitory activity of the extract of sindhu valladhi 
The microsome portion prepared from rat liver was used as the type 1 
isozyme source because it was more easily available  than that of the prostate. In 
this screening assay, the sindhu valladhi  showed the highest inhibitory activity . 
The extract of sindhu valladhi showed 5α-reductase inhibitory activity at dose 
dependently (IC50 = 93 ppm). It should be noted that finasteride, which is known 
as a potent steroidal inhibitor, showed an IC50 of  0.73 µM in our assay system. 
Generally, 5α-reductase type 2 is thought to play a major role in the prostate 
because it is predominantly expressed in this tissue. However, some evidence 
shows that, in the human prostate, 5α-reductase type 1 is expressed mainly in the 
epithelial cells, whereas 5α-reductase type 2 is localized mainly in the stromal 
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compartment (Thigpen et al., 1993;Bonkhoff et al., 1996). Because both isozymes 
are overexpressed in BPH tissue, we examined the inhibitory effect of the extract 
of sindhu valladhi against both  isozymes prepared from the prostate.. It is clear 
from the results that extracts of sindhu valladhi can inhibit both the types l and 2 
isozymes of the rat. 
 
Growth suppression of the rat prostate with administration of sindhu valladhi  
In this experiment, we used the anti-androgen receptor blockade flutamide 
not but 5α-reductase inhibitor such as finasteride as the positive control. It has 
been reported that the prostate size of animals treated with finasteride at 25 and 50 
mg/kg/day significantly decreased, but flutamide-treated animals exhibited 
complete feminization of the genitalia at 24 mg/kg/day (Imperato-McGinley et al., 
1992). Therefore we used a dose of l0 mg/kg/day of flutamide to inhibit the growth 
of the prostate. Four days after castration, the weights of the rat prostates were 
markedly reduced from 83.8±9.71 to 6.02±1.74 mg/100 g of body weight. The 
prostate weights recovered by s.c. injection of testosterone, but not completely.  
In the rats that received testosterone only, the prostate weight was 
39.72±10.76 mg/l00 g of the body weight. In the rats  that received testosterone 
and simultaneous administration of sindhu valladhi , this increase was reduced: the 
prostate weights were 26.62±4.57 mg/l00 g of the body weight.Flutamide also 
limited the testerone-induced  increase in prostate weights to 16.87±2.63 mg/l00 g 
of the body weight. 
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 Growth suppression of rat prostate with administration of  extracts of sindhu 
valladhi  
In the rats that received testosterone, administratio of  extracts of sindhu 
valladhi  reduced the increased weight of the ventral prostate .. 
Interestingly,administration of  extracts of sindhu valladhi  at the concentration of 
50 mg/kg showed higher suppression effects on the prostate. 
 
Discussion and conclusions 
Prostatic enlargement is dependent on tissue androgen, namely DHT, which 
is converted from testosterone by steroid 5α-reductase. In this study, we 
investigated the effects of sindhu valladhi on steroid 5α-reductase activity and on 
the testosterone-induced growth of the prostate in castrated rats. The extracts of 
sindhu valladhi inhibited both types of 5α-reductase, a so-called dual inhibition 
that might be advantageous for the therapy of BPH, since it has been shown that 
the dual inhibitor dutasteride is more powerful in reducing the DHT plasma 
concentration than selective type 1 or type 2 inhibitors (Graul et al., 1999). In 
addition, the treatment of sindhu valladhi itself or its extract significantly inhibited 
the testerone-induced growth of the ventral prostate in castrated rats. These results 
suggest that the suppression effect of prostatic growth by sindhu valladhi might 
come in part from its ability to act as an inhibitor of 5α-reductase. 
 In the last few years, the use of herbal therapies in alternative medicine has 
been increasing, and although the number of cancer patients using herbal dietary 
supplements is not exactly known, there is evidence of the increasing use of 
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dietary supplements in cancer treatment (Eisenberg et al., 1998). Considering our 
results, these effects might be related not only to the anti-cancer effects of sindhu 
valladhi but also to its anti-androgen effects.In this study, we found a new fact  to 
the biological activity of sindhu valladhi, anti-androgenic activities on in vitro 5α-
reductase and in vivo growth suppression of the rat prostate. In the future, herbal 
therapies will become more widely used for treatment of diseases. The anti-
androgenic activity of sindhu valladhi  is an important biological activity for use 
with BHP patients.  
 
 
 
 
Fig. 1. Inhibitory effects of sindhuvalladhi on  5α-reductase activities. Each 
column represents the mean±S.D.,n = 3. Sample concentration is 100 and  200 
ppm. 
0 20 40 60 80 100
100PPM
200PPM
% Inhibition
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Fig. 2. The inhibitory activity of sindhuvalladhi on types 1 and 2 5 α -reductase. 
Each column represents the mean±S.D., n=3.Sample concentration is 200 ppm. 
 
 
Fig. 3. Effects of sindhuvalladhi on testosteroneinduced 
regrowth of the castrated rat prostrate. Each column represents the mean±S.E.M., 
n = 6 . C: castrated rat, T: testosterone, SV: *p < 0.01 against C + T. 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE II RANDOMIZED CLINICAL TRAIL ON  VATHA VATHTHI 
KIRICHANAM(BENIGN PROSTATE HYPERPLASIA) WITH SINDHU VALLADHI 
FORM-I 
(SCREENING AND SELECTION PROFORMA) 
1.Name___________               2.Age_____   3.gender________  4.Phone no  _________ 
5. OP No. 6. IP No. 7. S.No.  . 
 INCLUSION CRITERIA:   
 Age : 50 & above 
 Sex :  male  
 Patient having symtoms of frequency,urency,incomplete emptying,weak 
steam,nocturia, 
 Patients who are willing to undergo USG investigation and give blood for laboratory 
investigation. 
 Patient willing to sign the informed consent stating that he will consciously stick to 
the treatment during 20 - 30 days but can opt out of the trial of  own conscious 
discretion.                
EXCLUSION CRITERIA:        
 Patient having ca prostate 
 Patient with cardiovascular disorder 
 Stricture urethra 
 Liver disease 
 Patient indicated for surgery 
 Patient with any other serious illness 
 Patient on those drugs which were likely to affect bladder function 
DATE  : 
STATION :      SIGNATURE OF  HOD 
 
 SIGNATURE OF INVESTIGATOR                           SIGNATURE OF LECTURER 
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GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE II RANDOMIZED CLINICAL TRAIL ON  VATHA 
VATHTHI KIRICHANAM(BENIGN PROSTATE HYPERPLASIA) WITH 
SINDHU VALLADHI. 
FORM l A     
    
HISTORY PROFORMA ON ENROLLMENT 
 
1. Serial No of the case:   _______________                           2. OP/IP No:_________ 
 
       
3. Name: ________________               4. Gender:  Male                     Female    
 
 
5. Age (years): _________   DOB            
      Date       Month            Year 
 
6.Address: -------------------------------------- 
                     -------------------------------------- 
 
7.A.Occupation:    -----------------------------                         B. Nature of work---------------
-- 
 
 
8. Educational  Status:   A) Illiterate                  B)Literate          
 
 
9.Height:---------- cms                10.Weight:----------kg 
 
11. Complaints and Duration:   
________________________________________________________________________ 
 
_______________________________________________________________________ 
 
12. Past History                     
 hypertension    ______________      
  
diabetes mellitus ______________      
  
asthma   ______________      
  
pt   ______________ 
 
HABITS 
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A) Smoking  : 1. Yes                 duration ________ years;    Number - _____     2. No  
 
B) Alcoholism:1. Yes                duration ________ years;    Quantity- ____ ml 2. No  
 
C) Tobacco chewing:  1. Yes                duration ________ years                          2.No 
                                     
D) Betel chewing     :  1. Yes                duration ________ years                          2.No 
 
 
13.Dietary style:   A.Pure vegetarian                B.Non-vegetarian                C. Mixed diet 
 
14. Drug history: Had the patient been treated before with allopathy drug?  
 
                                A) Yes                                    2) No                                     
 
15 Marital status :   1.Married         2.Unmarried                                                  
 
16. Family history : 
 
      Whether this problem runs in family?             1. Yes                               2.No   
  
       If yes, mention the relationship of affected person(s)  - 
___________________________                                                                                                                   
 
 18. Bowel habits & micturition:      Normal  
 
            History of habitual constipation              1.Yes                      2.No                                                      
 
            History of frequent diarrhoea                  1.Yes                      2.No                                                        
 
            History of frequent dysuria                     1.Yes                      2.No                
 
 
19. Psychological state:      Normal                    Anxiety                   Depression             
 
   
Date     :   
   
  Station      : 
 
 
  Signature of the Investigator : 
 
 
 
  Signature of the Lecturer  :                                            Signature of the HOD 
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             GOVERNMENT SIDDHA MEDICAL COLLEGE & HOSPITAL, 
PALAYAMKOTTAI, TIRUNELVELI DISTRICT 
DEPARTMENT OF POTHU MARUTHUVAM 
PRECLINICAL AND PHASE II RANDOMIZED CLINICAL TRAIL ON  VATHA 
VATHTHI KIRICHANAM(BENIGN PROSTATE HYPERPLASIA) WITH 
SINDHU VALLADHI 
FORM II & II-A 
 
CLINICAL ASSESSMENT ON ENROLLMENT AND ON VISITS 
 
1. S.NO:  _______                                             2. OP/IP NO : __________                            
      3.  Name : _______________________              4. Gender      : __________    
      5. Date of assessment : _____________              
 SIDDHA SYSTEM OF EXAMINATION 
1. ENVAGAI THERVU: [EIGHT-FOLD EXAMINATION] 
 I. NAADI: [PULSE PERCEPTION] 
 
     
   0stDay 
 
  07thDay 
  
  14th Day 
        
 21st Day  
 
 28th Day 
 
 30th Day 
Vali 
      
Azhal 
      
Iyyam 
      
Vali Azhal 
      
Azhal vali 
      
Iyya vali 
      
Vali Iyyam 
      
Azhal Iyyam 
      
 Iyya Azhal 
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II. NAA:[TONGUE] 
III.NIRAM: [COMPLEXION]    
0th 
Day 
 07th day 14th Day 21st Day 28th Day 30th day 
Dark/ 
Yellow/ 
tinted/ 
 Pale 
Dark/ 
Yellow/ 
tinted/   
 Pale 
Dark/ 
Yellow/ 
tinted/     
 Pale 
Dark/  
Yellow/ 
tinted /  
Pale                                                     
Dark/  
Yellow/ 
tinted/  
Pale 
Dark/  
Yellow/ 
tinted/  
Pale 
 
 
  0th Day 07th Day  14th Day   21st Day 28th Day 30th Day 
Colour Dark/         
Yellow/ 
Red/       
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Dark/ 
Yellow/ 
Red/ 
Pale 
Taste Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Sweet/ 
Bitter/ 
Sour/ 
Pungent/ 
None 
Coating Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Fissure Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Saliva Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Normal/ 
Increased/ 
Decreased 
Dryness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Glossitis Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Baldness Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
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IV.MOZHI: [VOICE] 
 
 
 
 
V.VIZHI: [EYES] (Lower palpabrel conjunctiva)   
    
 
 
 
 
VI. MALAM; [BOWEL HABITS / STOOLS] 
 
 
 
 
 
 
 
0th Day  07th day 14th Day 21st Day 28th Day 30th day 
Medium/ 
High/ 
Low / 
Pitched 
Medium/ 
High/ 
Low/ 
Pitched 
Medium/ 
High/ 
Low/ 
pitched 
Medium/ 
High/ 
Low/ 
pitched 
Medium/ 
High/ 
Low/ 
pitched 
Medium/ 
High/ 
Low/ 
pitched 
0th Day  07th day 14th Day 21st Day 28th Day 30th day 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
 0th Day 07th Day 14th Day  21stDay 28th Day 30th day 
Colour Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
 Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Dark/ 
Yellow/ 
Red/ Pale 
Consistency Solid/ 
Semisoli
d/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Solid/ 
Semisolid/ 
Watery 
Stool  bulk                         Normal/ 
Reduced 
 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Normal/ 
Reduced 
Constipation  Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Present/ 
Absent 
 
Diarrhoea Present/ 
Absent 
Present/ 
Absent 
Present/ 
Absent 
Present/
ERROR: syntaxerror
OFFENDING COMMAND: --nostringval--
STACK:
BT AT BT AT BT AT BT AT 1/2 hr 1 hr 1/2 hr 1 hr
1 2251 8100 9200 63 63 35 34 2 3 5 12 8 16 121 100 23 28
2 2263 8200 8100 63 65 30 32 5 3 24 35 3 6 110 100 26 24
3 2359 7500 8100 64 66 37 32 3 2 40 80 8 15 118 100 42 28
4 2501 9200 8500 64 64 32 33 4 3 18 40 6 12 115 95 29 26
5 2767 8300 8150 66 68 28 30 3 2 20 42 5 10 110 100 32 30
6 2770 10000 9800 60 64 30 33 4 3 20 30 4 10 100 100 32 25
7 2780 7900 8100 68 71 25 27 4 2 10 22 5 12 95 100 23 20
8 2831 7000 9100 59 66 40 33 1 1 14 30 5 10 127 110 36 34
9 2876 8400 9150 61 63 37 34 2 3 5 12 7 15 92 100 40 36
10 2951 7600 7000 57 57 38 38 3 5 22 44 11 22 144 73 39 29
11 3033 9100 8600 64 62 35 33 4 3 11 22 3 7 105 100 30 32
12 3116 9900 10100 57 62 28 33 2 2 5 15 5 11 85 95 33 28
13 3141 8000 8400 62 70 28 28 1 1 30 55 3 6 110 110 61 39
14 3167 8200 8600 63 65 30 32 3 2 22 44 5 12 80 90 30 30
15 3222 8300 8700 62 64 33 34 4 2 10 22 3 6 100 100 40 38
16 3223 9500 9900 67 70 25 27 3 2 5 11 3 6 95 95 32 28
17 3428 8500 9100 60 62 33 35 6 4 20 40 4 10 110 120 22 21
18 3563 8000 8300 68 68 28 30 4 2 10 22 6 12 100 100 35 34
19 3613 9000 9450 64 67 28 30 3 1 15 25 8 16 120 110 30 30
20 3624 8300 8700 65 66 30 32 2 1 25 55 5 10 110 110 35 30
TC
IP. NO
LABORATORY INVESTIGATION
AT
BT
Bl.Urea
N L E AT
DC ESR Bl.Sugar
BT AT
S.No
BT
BT AT BT AT BT AT BT AT 1/2 hr 1 hr 1/2 hr 1 hr
1 48765 8500 8700 60 62 37 36 3 2 18 40 4 8 124 106 36 34
2 50619 7700 7800 59 61 37 38 1 1 12 16 8 4 105 105 35 32
3 50740 7500 7600 52 53 46 46 2 1 11 22 4 8 86 85 23 22
4 52047 9100 9800 57 57 41 40 2 1 2 4 2 4 121 105 23 20
5 52597 9500 9200 64 63 34 34 2 1 1 2 2 3 284 180 35 30
6 53613 8000 8500 58 51 40 45 3 2 2 4 1 2 105 101 25 21
7 54405 8000 8500 65 66 33 33 2 1 10 30 5 15 117 122 26 26
8 55105 6400 8700 50 60 40 38 2 2 4 8 1 2 92 95 20 24
9 55308 8500 9000 66 68 27 29 3 1 4 8 1 2 80 85 25 13
10 61580 8700 8600 65 65 32 34 1 1 3 6 3 6 110 98 17 21
11 64331 8100 9400 63 57 33 41 2 1 1 2 1 2 96 100 26 15
12 66941 7800 7900 66 66 30 32 1 2 3 6 2 4 99 102 22 23
13 68139 8000 8600 67 67 29 30 2 2 6 12 2 4 110 130 34 24
14 71656 7900 8100 65 65 32 32 3 1 9 11 8 16 102 104 14 20
15 71657 8500 8900 65 56 32 36 1 2 6 13 4 8 53 75 37 24
16 72137 7900 7500 60 61 34 33 2 2 5 11 2 4 169 121 26 24
17 73906 9000 9500 62 64 32 34 1 2 8 16 4 8 169 117 26 26
18 76409 7900 8400 65 63 36 30 1 1 2 5 2 4 63 103 27 19
19 79422 7900 8100 65 67 30 32 3 1 15 25 5 10 76 86 22 22
20 82453 9900 9500 54 57 40 42 2 1 11 22 5 10 98 90 30 27
DC ESR
AT
Bl.Urea
N L E BT AT
BT AT BT
Bl.Sugar
S.No OP. NO TC
LABORATORY INVESTIGATION
Pus Cells Epi Cells RBC Cast/Crystal Pus Cells Epi Cells RBC Cast/Crystal
1 2251 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
2 2263 Nil Nil 1-2 - NAD NAD Nil Nil NAD NAD NAD NAD
3 2359 Nil Nil NAD few NAD NAD Nil Nil NAD NAD NAD NAD
4 2501 Nil Nil 1-3 NAD NAD NAD Nil Nil NAD NAD NAD NAD
5 2767 Nil Nil - few NAD NAD Nil Nil - NAD NAD NAD
6 2770 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
7 2780 Nil Nil 3-5 NAD NAD NAD Nil Nil NAD NAD NAD NAD
8 2831 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
9 2876 Nil Nil 2-3 NAD NAD NAD Nil Nil NAD NAD NAD NAD
10 2951 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
11 3033 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
12 3116 Nil Nil 2-3 few NAD NAD Nil Nil NAD NAD NAD NAD
13 3141 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
14 3167 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
15 3222 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
16 3223 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
17 3428 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
18 3563 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
19 3613 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
20 3624 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
Sugar Albumin Sugar
Deposits
Before treatment After treatment
LABORATORY INVESTIGATION
IP NOS.No Deposits
Albumin
Pus Cells Epi Cells RBC Cast/Crystal Pus Cells Epi Cells RBC Cast/Crystal
1 48765 Nil Nil 3-4 NAD NAD NAD Nil Nil 1-2 NAD NAD NAD
2 50619 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
3 50740 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
4 52047 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
5 52597 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
6 53613 Nil Nil 2-3 NAD NAD NAD Nil Nil 1-2 NAD NAD NAD
7 54405 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
8 55105 Nil Nil 2-3 NAD NAD NAD Nil Nil NAD NAD NAD NAD
9 55308 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
10 61580 Nil Nil 2-3 1-2 NAD NAD Nil Nil NAD NAD NAD NAD
11 64331 Trace Nil 1-3 1-3 NAD NAD Nil Nil NAD NAD NAD NAD
12 66941 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
13 68139 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
14 71656 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
15 71657 Nil Nil NAD 1-2 NAD NAD Nil Nil NAD NAD NAD NAD
16 72137 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
17 73906 Nil Nil NAD NAD NAD NAD Nil Nil NAD NAD NAD NAD
18 76409 Nil Nil 3-5 NAD NAD NAD Nil Nil NAD NAD NAD NAD
19 79422 Nil Nil 1-2 0-1 NAD NAD Nil Nil NAD NAD NAD NAD
20 82453 Nil Nil 1-2 NAD NAD NAD Nil Nil NAD NAD NAD NAD
Before treatment After treatment
Deposits
LABORATORY INVESTIGATION
Albumin Sugar Albumin Sugar
S.No OP. NO Deposits
BT AT BT AT BT AT
1 2251 Muthukumaraswamy 11 11.5 180 170 0.8 0.7
2 2263 Ramdoss 10.2 11 169 175 1 1.1
3 2359 Subbiah pillai 9 11 214 180 1.2 1
4 2501 Perumal pillai 12 11.2 209 180 0.7 0.7
5 2767 Naiynar 11.8 12.1 175 165 0.8 0.7
6 2770 Karuppaswamy 11.2 12 162 164 1.2 1.1
7 2780 Lakshmanan 10 11.8 182 180 0.8 0.9
8 2831 Lakshmanan 11 11.8 184 185 0.7 0.7
9 2876 Thatchana moorthy 11 12 118 124 0.7 0.8
10 2951 Sangiya 11.2 11.5 197 126 0.9 0.8
11 3033 Ganapathy 12 13 196 180 1.1 0.9
12 3116 Mangani 13 13 170 180 0.8 0.7
13 3141 Mayandi 10.2 11 175 188 0.9 0.7
14 3167 Mothilal 12 12.1 160 170 0.9 0.8
15 3222 Devanayagam 10.2 11.2 160 165 0.8 0.8
16 3223 Ponalagu muthu 10 11 180 170 1.1 0.9
17 3428 kasi 10.6 11 190 185 0.9 0.9
18 3563 Balaguru 9.6 10.8 180 170 0.8 0.8
19 3613 Ponniah 9.8 10.5 160 180 1 0.9
20 3624 Veerapandi 10.2 11 175 165 0.8 0.9
Serum Creatinine mg %
LABORATORY INVESTIGATION
Hb gm% Serum Cholesterol mg%IP.NoS.No Name
BT AT BT AT 0.9 0.8
1 48765 Sudalimuthu 11 12 196 180 0.9 0.9
2 50619 Subramanian 10.2 11 165 160 0.8 0.8
3 50740 Subramanian 12.5 13 196 187 0.7 0.7
4 52047 Vellaswamy 12.5 12 211 180 0.8 0.7
5 52597 Jeyasingh 11 12 181 170 0.9 0.8
6 53613 Ulaganathan 11.5 12.5 183 165 0.9 0.9
7 54405 Chelladurai 11 11.5 176 166 0.8 0.8
8 55105 Chelliah 11 11 156 156 0.8 0.9
9 55308 Muthiah 11 11.5 168 150 0.9 0.8
10 61580 Murugan 10.5 11 157 165 0.9 0.8
11 64331 Petchimuthu 11 12 145 150 1.1 0.9
12 66941 Mukkiah 12.5 13 157 153 1 0.9
13 68139 Vincent selvaraj 12.5 13 163 150 1.2 0.8
14 71656 Jeyaraj 11.2 12 180 180 0.9 0.8
15 71657 Selvaraj 13.6 13 154 148 1.3 1.2
16 72137 Nallakannu 11.5 12 156 145 0.8 0.8
17 73906 Kadarkariyandi 12 11 158 152 0.8 0.7
18 76409 Sethu Arumugam 12.5 13 143 140 0.9 0.8
19 79422 Chokalingam 13 13.5 229 220 0.8 0.8
20 82453 Natrajan 13.4 14 194 180 0.9 0.7
S.No OP.No Name Hb gm% Serum Cholesterol mg% Serum Creatinine mg %
LABORATORY INVESTIGATION
S.NO IP NO NAME AGE SEX OCCUPATION DOA DOD RESULT
IP OP TOTAL
1 2251 Muthukumaraswamy 85 M Retired Clerk 13.07.12 10.08.12 29 57 86 Good
2 2263 Ramdoss 77 M Farmer 14.07.12 13.08.12 31 92 123 Good
3 2359 Subbiah pillai 85 M Farmer 23.07.12 17.08.12 26 50 76 Fair
4 2501 Perumal pillai 65 M Farmer 31.07.12 20.08.12 21 85 106 Good
5 2767 Naiynar 70 M Driver 22.08.12 13.09.12 23 29 52 Good
6 2770 Karuppaswamy 60 M Farmer 22.08.12 26.09.12 36 64 100 Good
7 2780 Lakshmanan 65 M Coolie 22.08.12 13.09.12 23 36 59 Good
8 2831 Lakshmanan 72 M Coolie 27.08.12 17.09.12 22 29 51 Good
9 2876 Thatchana moorthy 75 M Farmer 31.08.12 23.09.12 24 71 95 Good
10 2951 Sangiya 70 M Tailor 06.09.12 02.10.12 27 43 70 Good
11 3033 Ganapathy 60 M Farmer 12.09.12 02.10.12 21 43 64 Good
12 3116 Mangani 81 M Coolie 19.09.12 11.10.12 23 29 52 Good
13 3141 Mayandi 70 M Coolie 21.09.12 18.10.12 28 29 57 Good
14 3167 Mothilal 73 M Coolie 22.09.12 12.10.12 21 50 71 Good
15 3222 Devanayagam 75 M Retired HM 25.09.12 19.10.12 25 43 68 Good
16 3223 Ponalagu muthu 66 M Tailor 25.09.12 15.10.12 21 22 43 Good
17 3428 Kasi 70 M Farmer 04.10.12 23.10.12 20 7 27 Good
18 3563 Balaguru 81 M Driver 13.10.12 02.11.12 21 29 50 Good
19 3613 Ponniah 77 M Retired 18.10.12 07.11.12 21 29 50 Good
20 3624 Veerapandi 72 M Farmer 19.10.12 07.11.12 20 29 49 Good
CASE SUMMARY
NO.OF.DAYS TREATED
S.NO OP. NO
NAME 
AGE SEX OCCUPATION DOA DOD TREATED DAYS RESULT
1 48765 Sudalimuthu 66 M Retired Person 29.06.12 21.09.12 85 Good
2 50619 Subramanian 68 M Farmer 05.07.12 20.09.12 78 Good
3 50740 Subramanian 77 M Farmer 06.07.12 28.09.12 85 Good
4 52047 Vellaswamy 63 M Retired Person 10.07.12 28.08.12 50 Good
5 52597 Jeyasingh 75 M Retired Person 12.07.12 27.09.12 78 Good
6 53613 Ulaganathan 68 M Retired Person 16.07.12 01.10.12 78 Good
7 54405 Chelladurai 59 M Tailor 08.07.12 29.11.12 145 Good
8 55105 Chelliah 70 M Retired Person 21.07.12 01.12.12 134 Good
9 55308 Muthiah 75 M Retired Person 21.07.12 24.11.12 127 Good
10 61580 Murugan 50 M Farmer 11.08.12 21.11.12 103 Good
11 64331 Petchimuthu 77 M Retired Person 21.08.12 06.11.12 78 Good
12 66941 Mukkiah 56 M Tailor 30.08.12 29.11.12 92 Good
13 68139 Vincent selvaraj 62 M Retired Person 03.09.12 12.11.12 71 Good
14 71656 Jeyaraj 67 M Retired Person 13.09.12 29.11.12 79 Good
15 71657 Selvaraj 84 M Farmer 13.09.12 29.11.12 79 Fair
16 72137 Nallakannu 65 M Retired Person 14.09.12 30.11.12 79 Good
17 73906 Kadarkariyandi 63 M Farmer 20.09.12 06.12.12 79 Fair
18 76409 Sethu Arumugam 61 M Retired Person 27.09.12 06.12.12 72 Good
19 79422 Chokalingam 75 M Retired Person 06.10.12 01.12.12 57 Good
20 82453 Natarajan 60 M Retired Person 16.10.12 04.12.12 50 Good
CASE SUMMARY
SL.NOIP.NO NAME PSA
Prostate 
Specific 
Antigen
BT AT BT AT BT AT BT AT
1 2251 Muthukumaraswamy 1.1 4.8*4.5*3.4 4.2*4.0*3.1 25.00 25.00 80.00 8 3
2 2263 Ramdoss 1.8 3.8*4.1*4.5 3.8*3.8*4.3 40.00 35.00 28.00 24.00 10 3
3 2359 Subbiah pillai 3.9 3.50*4.46*4.0 3.1*4.0*3.8 28.00 25.00 210.00 108.00 35 28
4 2501 Perumal pillai 3.2 3.4*4.8*4.1 3.1*4.0*3.5 35.20 26.00 56.00 23.00 29 7
5 2767 Naiynar 2.8 4.0*4.0*4.1 3.7*4.0*3.2 35.00 30.00 20.00 15.00 14 4
6 2770 Karuppaswamy 2.7 4.15*3.50*4.23 3.8*3.5*4.0 32.16 27.00 32.00 21.00 22 3
7 2780 Lakshmanan 2.9 4.0*4.5*3.0 3.5*4.1*3.0 36.00 32.00 54.00 15.00 11 2
8 2831 Lakshmanan 1.5 3.8*4.2*3.7 3.2*4.0*3.3 38.00 32.00 40.00 18.00 14 3
9 2876 Thatchana moorthy 0.9 4.1*4.6*3.7 3.8*4.0*3.1 30.00 28.00 23.00 20.00 10 2
10 2951 Sangiya 1.1 4.55*4.39*4.32 4.1*4.0*4.1 45.22 39.07 60.00 25.00 25 3
11 3033 Ganapathy 0.5 3.9*3.8*3.9 3.5*3.9*3.1 32.00 26.00 45.00 24.00 19 3
12 3116 Mangani 1.9 3.9*3.2*4.2 3.5*3.0*4.1 36.00 31.00 18.00 18.00 15 2
13 3141 Mayandi 2.5 3.8*4.3*3.8 3.4*3.9*3.2 46.00 40.00 38.00 23.00 19 2
14 3167 Mothilal 3.1 3.8*4.3*3.9 3.4*4.0*3.7 38.00 32.00 75.00 24.00 14 3
15 3222 Devanayagam 3.6 3.3*3.8*3.2 3.2*3.7*3.2 21.88 21.00 80.00 20.00 26 5
16 3223 Ponalagu muthu 2.1 3.78*4.46*3.64 3.5*4.2*3.2 33.00 28.00 17.00 20 2
17 3428 Kasi 1.8 3.65*3.71*3.53 3.41*3.6*3.1 25.02 24.00 5.00 32 3
18 3563 Balaguru 3.5 4.18*3.72*3.82 3.98*3.4*3.5 31.14 29.00 36.00 18.00 23 4
19 3613 Ponniah 1.9 4.8*4.8*4.7 4.46*4.35*4.34 51.00 44.04 33.00 20.00 28 4
20 3624 Veerapandi 2.2 4.6*4.6*3.6 4.4*4.0*3.5 32.00 30.00 18 3
CASE SUMMARY
IPSS SCOREProstate
Size (c.m) Volume (cc)
Post Residual 
Urine Volume
 SL.NOOP.NO NAME PSA
Prostate 
Specific 
Antigen BT AT BT AT BT AT BT AT
1 48765 Sudalimuthu 1.8 3.73*4.22*3.70 3.1*4.0*2.9 30.51 28 38 24 24 7
2 50619 Subramanian 2.4 4.5*4.0*4.5 3.5*4.0*3.8 47 35 19 18 27 4
3 50740 Subramanian 3.2 4.8*4.2*3.7 4.0*4.0*3.1 55 45 28 21 19 3
4 52047 Vellaswamy 3.7 4.0*4.6*4.2 3.5*4.1*3.6 41 35 36 21 9 1
5 52597 Jeyasingh 2.8 3.8*5.4*3.2 3.4*4.5*3.1 34 29 52 24 8 3
6 53613 Ulaganathan 1.2 4.1*4.7*4.4 3.8*3.8*4.1 46 42 40 25 13 2
7 54405 Chelladurai 2.8 4.41*3.63*4.54 3.8*3.5*4.1 38.09 32 40 23 14 3
8 55105 Chelliah 1.8 5.1*4.1*5.9 4.0*4.0*4.8 63.3 53 100 19 28 5
9 55308 Muthiah 2.2 4.6*5.1*5.1 4.3*4.1*3.9 65 57 35 22 28 5
10 61580 Murugan 1.9 5.0*3.7*3.5 4.5*3.5*3.5 33 28 28 18 21 4
11 64331 Petchimuthu 3.2 4.8*4.7*4.8 4.6*4.5*4.1 58 40 60 23 13 2
12 66941 Mukkiah 3.7 3.6*4.12*3.60 3.5*3.9*3.1 31.8 25 59 25 25 3
13 68139 Vincent selvaraj 2.2 4.21*3.86*4.40 3.9*4.0*4.1 37.39 32 60 19 26 4
14 71656 Jeyaraj 1.8 3.7*4.4*3.3 3.5*4.1*3.0 29.41 25 28 18 20 4
15 71657 Selvaraj 1.2 5.0*3.9*3.9 4.8*3.9*3.7 39.8 31 788 300 30 21
16 72137 Nallakannu 2.6 3.9*4.6*4.0 3.6*4.0*3.5 38.1 32 17  25 3
17 73906 Kadarkariyandi 2.4 4.15*3.38*4.36 3.9*3.3*4.2 31.99 27 600 251 30 18
18 76409 Sethu Arumugam 2.1 3.9*4.3*4.3 3.6*4.1*3.8 38.24 29 38 19 17 4
19 79422 Chokalingam 1.8 3.7*5.3*4.1 3.5*4.0*3.8 43 36 66 21 23 4
20 82453 Natrajan 1.4 3.9*3.8*4.7 3.6*3.5*4.5 36.6 29 32 18 35 6
CASE SUMMARY
IPSS SCORE
Size (c.m) Volume (cc) Post Residual 
Prostate
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